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ABSTRACT 
Tuberculosis is the leading cause of death from a single infectious agent in the world, 
surpassing the annual death toll of both malaria and HIV combined. The rise in multidrug-
resistant tuberculosis (MDR-TB) has further exacerbated the situation, as this form of TB is 
more difficult and time-consuming to treat, with dismal cure rates. There is an urgent need to 
improve treatment of MDR-TB and to avoid the development of resistance during TB 
treatment. This thesis will delve deeper into the intricate relationship of bacterial resistance, 
drug exposure and host response, with the aim of exploring the role of repurposed drugs, the 
importance of the level of drug resistance of TB-drugs as well as therapeutic drug monitoring 
in the fight against TB and MDR-TB. 
Repurposing already approved drugs may accelerate the availability of new drug alternatives 
and two such alternatives were explored in Study I & II. The minimum inhibitory 
concentration (MIC) in vitro was determined for trimethoprim-sulfamethoxazole and 
meropenem-clavulanic acid, showing good activity against highly drug-resistant 
Mycobacterium tuberculosis (M.tuberculosis) isolates. Explorative pharmacometric 
modelling showed a high probability of target attainment for clinically achievable doses of 
trimethoprim-sulfamethoxazole (800 mg sulfamethoxazole thrice daily). However, there are 
no clinical trials evaluating the effect of trimethoprim-sulfamethoxazole in MDR-TB 
treatment. Meropenem-clavulanic acid is recommended by World Health Organization as an 
add-on agent in difficult to treat cases.  
The importance of the level of bacterial resistance was explored in Study III, a national 
cohort study in Sweden including all MDR-TB cases from 1992-2014 (no= 158). Increments 
of MIC for fluoroquinolones, rather than binary resistance testing, were associated with 
increased risk of unsuccessful treatment outcome. A similar association was seen for 
increasing age and patients with diabetes. Furthermore, pyrazinamide treatment was 
associated with reduced time to sputum culture conversion for patients with pyrazinamide-
susceptible M.tuberculosis isolates. 
Bacterial resistance, as well as individual drug exposure, were studied in Study IV, where 
drug concentrations were measured in a prospective cohort study of susceptible TB. The drug 
exposure of first-line drugs in TB-patients was often lower than recommended (16-42%), 
despite the use of recommended dosages. The number of patients with low drug 
concentrations of rifampicin was particularly pronounced (13/31, 42%), with great inter-
individual variability. When taking individual MICs into account, the ratios of drug exposure 
and the MICs were still low, possibly contributing to the overall successful treatment 
outcome. Subtherapeutic drug exposure can be revealed by therapeutic drug monitoring. The 
result of this study has led to the development of a prospective cohort study in China, 
studying drug exposure in relation to bacterial MIC in MDR-TB patients.  
In conclusion, a more holistic approach, taking the level of bacterial susceptibility, individual 
drug exposure as well as comorbidities into account, is needed for an individualised, 
improved treatment of TB. For clinicians, therapeutic drug monitoring might be a useful tool 
for selected patients, with the aim of preventing acquired drug resistance and improving 
treatment outcome of TB and MDR-TB.  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
”Hur kan det få vara så hemskt, frågade jag, hur kan det få vara så hemskt att en del måste 
dö, när dom inte har fyllt tio år ens?” 
Skorpan, döende i tuberkulos, till Jonathan ur Bröderna Lejonhjärta 1973 av Astrid Lindgren 
Från att ha varit en farsot i det svenska samhället under många århundraden, har tuberkulos 
blivit en ovanlig dödsorsak i Sverige. Så ser det dessvärre inte ut i resten av världen. Faktum 
är att tuberkulos är den infektionssjukdom som skördar flest liv årligen, mer än HIV/AIDS 
och malaria sammanlagt. Förra året dog mer än en och en halv miljon människor av 
tuberkulos. Tuberkulos är en social sjukdom som starkt påverkas av den miljö man lever i 
och där trångboddhet, undernäring och bristande tillgång till sjukvård ökar risken för 
insjuknande. Tuberkulos orsakas av bakterien Mycobacterium tuberculosis (M.tuberculosis) 
och sprids via luften i små droppar via hosta från en tuberkulos-sjuk och kan vid sjukdom ge 
symtom som långvarig, ibland blodig hosta och utmärgling. Under framförallt 1700-talet till 
1900-talets första hälft var Sverige liksom resten av Europa svårt drabbat av tuberkulos, eller 
lungsot som det också kallades. Så här beskrev stadsläkaren och professorn Klas Linroth 
tuberkulosens framfart i Stockholm 1880: ”Lungsoten, vår stads liksom andra orters värsta 
mordengel”. Under början av 1940 var antal nya fall per år över 300 per 100 000 innevånare, 
liknande situationen i Sydafrika i dag. 
Tuberkulos är möjlig att utrota då människan är enda smittbäraren, så varför dog så många 
människor förra året av en behandlingsbar sjukdom? Bristande tillgång till sjukvård, 
läkemedel, utebliven diagnostik och smittspårning samt ökad andel av läkemedelsresistent, 
dvs. motståndskraftig mot ett eller flera läkemedel, tuberkulos är några delförklaringar. 
Känslig tuberkulos, utan läkemedelsresistens, behandlas i minst 6 månader med fyra 
läkemedel. Multiresistent tuberkulos (MDR-tbc) definieras som M.tuberculosis med resistens 
mot de två viktigaste läkemedlen rifampicin och isoniazid och med fler än 500 000 nya fall 
årligen är det ett stort hot mot folkhälsan i världen. Behandlingen av MDR-tbc är upp till två 
år med många biverkningar och den globala utläkningen är endast 54 %. De enda nya 
läkemedel som framtagits under de senaste 40 åren är bedaquiline och delamanid. Dessa kan 
komma att förbättra överlevnaden hos individer med resistent tuberkulos, men bara 10 % av 
de patienter som behöver dem får tillgång till de nya läkemedlen.  Därför behövs billiga, 
tillgängliga alternativa läkemedel. 
Syftet med avhandlingen är att undersöka nya strategier för att förbättra behandlingen av 
tuberkulos och MDR-tbc genom att: 
 återanvända äldre antibiotika och undersöka dess effekt på läkemedelsresistent 
M. tuberculosis (Studie I & II) 
 studera förhållandet mellan bakteriens grad av resistens och 
behandlingsutfallet av MDR-tbc (Studie III) 
 bestämma läkemedelskoncentrationerna i blodet hos tuberkulospatienter i 
Sverige och förhållandet till bakteriens grad av resistens (Studie IV) 
  
Då äldre antibiotika redan finns tillgängliga och ofta är billiga är de en potentiell källa till nya 
läkemedelsalternativ vid svårbehandlad tuberkulos. Därför studerade vi effekten av Bactrim 
(trimethoprim-sulfamethoxazole, TMP-SMX), ett sulfa-innehållande läkemedel som tidigare 
ofta användes mot exempelvis urinvägsinfektioner. Multiresistenta M.tuberculosis bakterier 
på odlingsplattor utsattes för TMP-SMX i stigande koncentrationer för att finna den minsta 
hämmande koncentrationen, dvs. den lägsta koncentrationen av läkemedlet som dödar all 
synlig växt (Studie I). Vi fann att de koncentrationer som krävdes för att döda bakterierna 
bör kunna uppnås och tolereras i människa. Vidare undersöktes effekten på multiresistent 
M.tuberculosis av meropenem-clavulansyra (MEM-CLA), ett intravenöst läkemedel som 
vanligen används vid svåra fall av blodförgiftning (Studie II). Här såg vi också god 
avdödning av tuberkulosbakterien i labbmiljö när MEM-CLA tillsattes. TMP-SMX och 
MEM-CLA har dock inte utvärderats i tillräcklig grad i kliniska studier för att säkerställa dess 
effekt hos patienter med aktiv tuberkulossjukdom. 
Vidare önskade vi utröna huruvida ökad resistens hos tuberkulosbakterien påverkar 
behandlingsutfallet. I en nationell studie med alla fall av MDR-tbc från 1992-2014 (nr= 158) 
fann vi att ökad grad av bakteriell resistens, mätt som den minsta hämmande koncentrationen, 
var associerat till en ökad risk för död, utebliven läkning samt återfall av tuberkulos (Studie 
III). Även stigande ålder samt diabetes var riskfaktorer för sämre behandlingsutfall av 
tuberkulos. Gällande behandlingen av MDR-tbc fann vi att läkemedlet pyrazinamid till rätt 
patienter, där resistensbestämning visat känslighet hos bakterien för pyrazinamid, var 
förknippad med förkortad längd av smittsamhet hos lungsjuka MDR-tbc patienter. Studien 
tillförde viktiga kliniska kunskaper att beakta vid behandlingen av MDR-tbc. 
Graden av bakteriell resistens studerades också i Studie IV, där även 
läkemedelskoncentrationer i blodet uppmättes hos tuberkulospatienter med känslig tuberkulos 
från två svenska sjukhus (nr=31). Låga läkemedelskoncentrationer av förstahandsläkemedlen 
mot tuberkulos var vanliga (16-42 %), trots rekommenderade doseringar av medicinerna. I 
synnerhet noterade vi låga nivåer i blodet av det vitala läkemedlet rifampicin, (13/31 
patienter, 42 %), vilket i tidigare studier har medfört ökad risk för sämre behandlingsutfall 
och resistensutveckling. Behandlande läkare bör vara uppmärksam på att 
läkemedelskoncentrationer kan behöva kontrolleras för att säkerställa adekvat 
läkemedelsexponering. Trots de låga läkemedelskoncentrationerna var behandlingsresultaten 
goda (100 % utläkning initialt, dock två återfall), möjligtvis pga. den låga graden av resistens 
hos tuberkulosbakterierna. Då behandlingen av resistent tuberkulos är ännu mer komplicerad 
då en kombination av minst fem läkemedel krävs har vi genomfört en liknande studie i Kina 
var vi undersöker läkemedelskoncentrationerna vid behandlingen av MDR-tbc där resultaten 
väntas nästa år. Sammanfattningsvis tyder vår forskning på att behandlingen av tuberkulos 
bör individualiseras, genom att graden av resistens, läkemedelsexponeringen i blodet samt 
kliniska faktorer som exempelvis diabetes och annan samsjuklighet tas i beaktning. 
Under de fyra åren av mina doktorandstudier har mer än 40 miljoner människor nyinsjuknat i 
tuberkulos. I denna avhandling beskrivs olika strategier för att försöka förbättra behandlingen 
och överlevnaden av tuberkulos, men om vi ska nå Världshälsoorganisationens mål om att 
utrota sjukdomen till 2050 behövs större, globala satsningar inom folkhälsa och sjukvård. För 
att svara Skorpan i Bröderna Lejonhjärta, ingen ska behöva dö av denna behandlingsbara 
sjukdom, varken gammal eller ung!  
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1 PREFACE 
 
“Please don’t transfer me to the TB-ward – it’s a death sentence!” 
 
The 26-year old father of two pleaded with me not to transfer him from the medical ward to 
the tuberculosis (TB) ward, now that his TB diagnosis had been confirmed. His fears were 
not unjustified. Due to lack of isolation rooms and months of delays in receiving results of 
susceptibility patterns, highly resistant M.tuberculosis strains spread in the ward and 
mortality was staggeringly high. 
 
This was the reality in 2007 in COSH hospital, Tugela Ferry, South Africa. During my year 
as a Senior Medical Officer in the hospital, I witnessed the extremely high mortality rate 
(96%) that has been reported from the hospital amongst multidrug-resistant TB patients co-
infected with HIV (1). Most of the patients were of a similar age to me when they died. This 
experience has profoundly motivated my choice of career and research field. 
 
There were many factors contributing to the high TB mortality in the region, such as delays in 
diagnosis, high levels of HIV comorbidity, poor logistics, overwhelmed health services as 
well as weak drug regimens. Although new highly effective drugs have recently become 
available against MRD-TB, there are already reports of acquired drug resistance. Eleven 
years later I can say that the solution is not just new, effective drugs; we need to take better 
care of the drugs we have. We need more knowledge about the intricate relationship between 
host, pathogen and drug.  
 
A few weeks later I went to visit the same patient in the TB-ward, only to find that he had 
passed away. A week later, the DST result finally became available and revealed that none of 
the drugs he had been treated with were effective. 
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2 INTRODUCTION 
2.1 TUBERCULOSIS – AN OVERVIEW 
“Where youth grows pale, and spectre-thin and dies”                                                          
“Ode to a Nightingale”, by John Keats, who died at the age of 26 of TB. 
The historic, almost romantic, notion of tuberculosis (TB) has since long been surpassed by 
stigma. TB, caused by the bacteria Mycobacterium tuberculosis (M. tuberculosis), was for a 
long time seen as a disease of the deprived, due to its rapid spread in poor, malnourished 
people. In recent decades, the stigmatisation has been exacerbated by the association with 
HIV (2). TB had a substantial impact on Swedish society during the 18th to early 20th 
century, with an incidence in 1940 of 300/100 000 inhabitants, comparable to the current 
incidence of TB in South Africa. Since the late 1940s, there has been a dramatic drop in TB 
incidence in Sweden to approximately 5 cases/100 000 a year (3). Nevertheless, TB is still a 
global health emergency world-wide. 
2.1.1 Tuberculosis epidemiology worldwide 
TB is now the leading infectious disease killer as an infective agent, surpassing HIV/AIDS 
and malaria combined. There were an estimated 10 million new cases in 2017 and 
distribution world-wide is shown in Figure 1 (4).  
 
Figure 1. Global incidence of tuberculosis 2016. 
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The incidence of TB is decreasing roughly 2% annually, whereas the TB mortality rate is 
falling approximately 3% per year globally. Despite this decrease, there were more than 3500 
casualties per day worldwide in 2016 due to TB. The annual death toll of TB is close to 1.6 
million people (4). Over 95% of all TB deaths occur in resource-limited countries, although 
the total death rate of TB worldwide has almost halved from 1990 to 2015 (5). Currently, 
around 16% of patients with TB die from their disease. The World Health Organization 
(WHO) End TB Strategy aims for a 95% reduction in TB deaths and a 90% reduction in new 
TB cases from 2015 to 2035 with the goal of TB elimination. The decrease in new TB cases 
and mortality has to be substantially accelerated if these goals are to be achieved. The global 
treatment success rate of TB of is 83%, close to the WHO goal of >85% (6). However, a 
major obstacle against TB control and elimination is the estimated one-third of all active TB 
cases world-wide that never get diagnosed or reported (4). 
2.1.2 Clinical aspects of TB 
As an airborne infection, TB is a social disease, affecting mainly household and close 
contacts. An infectious TB patient typically infects around 3-6 people per year and is not as 
highly contagious as other air-borne pathogens, such as the measles virus (7). After infection, 
individuals may develop so-called latent TB infection, defined as a positive tuberculin skin 
test or interferon-gamma release assay (IGRA) without symptoms and signs of TB, including 
a normal chest x-ray (8). Latent TB can reactive years later and the risk increases with 
immunosuppression or the use of immunosuppressant drugs such as TNF-α inhibitors. 
Indeed, HIV infection, in particular untreated, is the strongest risk factor for TB disease (9). 
However, malnutrition is more common in absolute numbers and thought to be attributed to 
27% of TB cases worldwide (10). The individual´s immune status is paramount in controlling 
M.tuberculosis, with only 5-10% of infected people developing active TB during their 
lifetime. Upon inhalation, M.tuberculosis is phagocytosed by resident lung macrophages in 
which they may replicate due to active blockage of the fusion with the lysosome, ensuring its 
survival (11). After an incubation time of 6-8 weeks, the classic symptoms of pulmonary TB 
(PTB) are prolonged cough, night-sweats, weight-loss and fever, although approximately 
25% of TB patients have no or few symptoms (12). In the natural course of TB before 
effective treatment with antibiotics, up to 25% of people with active TB will be cured of the 
disease, whereas around 50% will die and the rest develop chronic disease (13). Old 
granulomas can be seen as calcified scars on a chest x-ray, where M.tuberculosis can lie 
dormant, metaphorically in calcified sarcophaguses, while awaiting an opportunity to resurge 
(14).  
2.1.3 The pathogen – M.tuberculosis 
M.tuberculosis is a slow-growing aerobe rod-shaped facultative intracellular bacteria, 
characteristically acid-fast when microbiological staining techniques are used (15). The 
M.tuberculosis complex consists of the genetically linked M.tuberculosis and rare causes of 
TB disease such as M.africanum, the zoonotic M.bovis, M.microti and M. caprae. The thick, 
lipid-rich cell wall makes the bacteria resilient to drying. M.tuberculosis can thrive extra- and 
intracellularly, extracellularly early on or in disseminated disease but typically resides inside 
the macrophage (16). Activated macrophages, T lymphocytes as well as tumour necrosis 
factor (TNF-α), interleukin-12 and interferon-λ are vital for the formation of a granuloma, 
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with the aim of killing and preventing dissemination of the bacteria (17). In the granuloma’s 
harsh conditions with anoxia and depleted nutrients, the replication is slowed. A further step 
is the complete halt of replication without bacterial death, when the bacteria enters a dormant 
stage and can remain viable without causing active disease. Later immunosuppression can 
lead to reactivation years later, where dormant bacilli multiply, causing active TB (18). 
Figure 2. Hypothetical model of three subpopulations of M.tuberculosis, depending 
on growth. 
 
Illustration by Paul Garbers adapted from ‘A clinician’s guide to tuberculosis’ Iseman 2000. 
The immune system can often control bacterial growth by an effective cell-mediated immune 
response, but cannot always eradicate bacilli in the slowly replicating phase or even dormant 
bacteria, known as persisters, a major cause of relapse and reactivation (Figure 2) (19). 
Sterilizing activity of a drug refers to the killing of the last viable bacteria, such as persisters 
and slowly multiplying bacilli (20, 21). 
2.1.4 Treatment of susceptible TB 
The scientific efforts in the 40s and 50s to find a cure for TB finally resulted in the ground-
breaking turning point where TB changed from a deadly to a curable disease (22). 
Unfortunately, as a result of monotherapy, resistance soon emerged and it became evident 
that a combination of drugs was mandatory (23). Standard treatment of TB involves an 
intensive phase of two months with the first line drugs, rifampicin, isoniazid, pyrazinamide 
and ethambutol, followed by a continuation phase of four months with only rifampicin and 
isoniazid.  
The drug regimen is designed to kill all different subpopulations of M.tuberculosis isolates 
(Figure 2). M.tuberculosis is killed bi-phasically, where fast-replicating bacteria are rapidly 
killed by the highly bactericidal isoniazid, whereas persisters and slowly replicating bacteria 
require drugs with sterilising activity such as rifampicin and pyrazinamide, as well as long 
Population A: Rapidly multiplying (caseum) 
Population B: Slowly multiplying (acidic environment) 
Population C: Sporadically multiplying (persisters) 
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treatment periods to avoid relapse (24-26). The lipophilic nature of rifampicin allows activity 
of intracellular bacteria (27). Pyrazinamide also has good penetration and activity in the 
acidic environment in caseating granulomas (20, 28).  
Together, the first-line drugs target different subpopulations of M.tuberculosis with varying 
metabolic activity and location (29) with isoniazid being most effective against rapidly 
dividing bacteria, pyrazinamide most effective in acidic environments and rifampicin most 
effective as a sterilising agent of persisting bacteria (Figure 2). 
2.1.5 Principles of M.tuberculosis resistance  
The main mechanism of drug resistance in M.tuberculosis is spontaneous chromosomal 
mutations. These mutations will result in resistance through drug target alterations, 
overexpression of drug target, disruption of prodrug activation (for example katG and 
isoniazid) and the activation of efflux pump (30). In a bacterial population, mutations occur 
naturally at a low rate (108 for rifampicin and 106 for isoniazid) and are unlikely to multiply 
in a well-designed multi-drug TB therapy (31). Thus, acquired drug-resistance in 
M.tuberculosis is primarily a man-made phenomenon that develops mainly through low drug-
exposure in the patient due to, for example, underdosing, poor adherence, poor quality drugs, 
irregular drug supply or poor drug absorption (29, 32).  
2.1.6 The MDR-TB epidemic – TB resurges 
The WHO End TB Strategy aims for a world free of TB in 2050 (33). Although susceptible 
TB is slowly decreasing worldwide, the reduction rate is too slow (2%) and MDR-TB are 
increasing (6). MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) are defined 
in Table 1. 
 
Table 1. Definitions of drug-resistant tuberculosis. 
 
* The same recommended treatment as for MDR-TB according to WHO 
* Definition of XDR-TB likely to change due to updated treatment recommendations where second-line 
injectable drugs have been downgraded.  
RR-TB* M.tuberculosis resistant to rifampicin 
MDR-TB M.tuberculosis resistant to rifampicin and isoniazid  
pre-XDR-TB MDR-TB with additional resistance to any fluoroquinolone 
(ofloxacin, moxifloxacin, levofloxacin) OR injectable drug 
(capreomycin, kanamycin, amikacin) 
XDR-TB** MDR-TB plus resistance to: any fluoroquinolone (ofloxacin, 
moxifloxacin, levofloxacin) AND any injectable drug 
(capreomycin, kanamycin, amikacin) 
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WHO estimates that 558 000 new MDR/RR-TB cases emerged in 2017 alone, of which the 
vast majority (71%) were not diagnosed or reported and only a quarter was started on 
treatment (4). As drug resistance is increasing, drug susceptibility testing (DST) is needed for 
accurate treatment of TB, but is often not performed in many high-burden countries. In many 
settings, only sputum from retreatment TB-patients receive primary DST. However, the fact 
that 38% of Belarus patients without previous TB treatment were found to have MDR-TB in 
2016 (6), exemplifies the need of initial DST for all patients, in order to avoid missing drug-
resistant TB. Even if MDR-TB is identified, only 36% of MDR-TB patients receive DST for 
second-line drugs (34).   
Almost half of the world’s burden of MDR-TB is found in India, China and the Russian 
Federation (4) (Figure 3). Although Europe has less than 5% of all TB, it has a 
disproportionate 25% of the total burden of MDR-TB in the world. The number of MDR-TB 
patients Sweden, although still low around 3%, is increasing as a reflection of the MDR-TB 
epidemic at large (35). 
 
Figure 3. World-wide distribution of MDR-TB 2017. 
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2.1.7 Diagnosis of TB and MDR-TB – “going for the bug” 
Rapid and correct diagnosis of TB is vital to achieve infection control. M.tuberculosis is 
detected by smear microscopy and by PCR, including point-of-care tests. Mycobacterial 
culture requires technical expertise as well as a well-equipped biosafety level 3 (BSL-3) 
laboratory and is not widely available.  Smear microscopy positivity is a marker of high 
infectiousness, with more than 5,000-10,000 bacteria/ml of sputum required for visual 
detection (36). The use of PCR for the detection of M.tuberculosis greatly increases the 
sensitivity for sputum samples, from 50% with smear microscopy to around 70-95% with 
PCR, depending on bacterial load (37, 38) as compared to culture. Culture to detect 
M.tuberculosis remains as a reference method and the solid egg-based Löwenstein-Jensen 
(LJ) is the most commonly used media worldwide. The introduction of liquid broth systems 
such as BACTEC in the 1980s, reduced the mean time-to-detection of positive growth to 1-2 
weeks for smear positive samples, compared to 3 weeks on solid media (39).  
 
2.2 DRUG RESISTANCE IN M.TUBERCULOSIS 
2.2.1 Defining resistance in TB 
In every M.tuberculosis population there is heterogeneity and a number of strains will, by 
spontaneous mutations, differ from the rest of the bacteria by their ability to grow, despite the 
presence of an active antibiotic. Depending on the extent of the proportion of resistant 
subpopulations, this might affect clinical outcome. Therefore, resistance is defined as more 
than 1% of growth in the presence of the critical concentration of a drug (40).    
The critical concentration has recently been redefined by WHO as “the lowest concentration 
of an anti-TB agent in vitro that will inhibit the growth of 99% (90% for pyrazinamide) of 
phenotypically wild-type strains of M.tuberculosis complex” (40).  Critical concentrations are 
method-specific and should ideally separate the wild-type population from the non-wild-type. 
Overlapping distributions of the two populations in combination with high methodological 
variability of some drugs decreases DST reproducibility, as seen for ethambutol (41). The 
epidemiological cut-off (ECOFF) is the highest MIC within the wild-type population, i.e. 
encompassing >99% of isolates lacking phenotypic resistance (Figure 4) (40).  
A clinical breakpoint should separate strains that are likely to respond, as opposed to being 
unlikely to respond to treatment, and should be defined by considering the ECOFF, in 
relation to antimicrobial exposure and microbial kill, as well as clinical outcome (42). 
Unfortunately, there are few defined clinical breakpoints for TB-drugs and critical 
concentrations are often used, since extensive clinical outcome data are lacking (40, 43, 44).  
  
  9 
Figure 4. Schematic illustration of the relationship between ECOFF, critical 
concentration and clinical breakpoint. The critical concentration and the clinical 
breakpoint (if defined) regularly coincide. The number of MIC dilution steps has been 
increased for clarity. 
 
As Canetti eloquently stated already in 1963, resistance is defined in a laboratory 
environment and does not automatically correspond to clinical treatment failure. Rather, the 
presence of M.tuberculosis resistance in vitro should be viewed as a decreased probability of 
treatment success in vivo (45), in agreement with other bacteria. 
2.2.2 Methods of drug susceptibility testing  
Mycobacterial resistance can be measured by molecular or phenotypic methods. DST is 
mainly performed using the indirect method, such as from cultured isolates. Direct DST, i.e. 
from sputum samples (smear and/or PCR positive), is sometimes used for molecular methods 
such as line-probe assays (LPAs).  
2.2.2.1 Molecular DST – to rapidly rule in, but not rule out resistance 
Molecular methods use DNA sequences to detect known mutations linked to phenotypic 
resistance. The mutations might consist of single nucleotide polymorphisms (SNPs), 
deletions or insertions and genomic rearrangements, giving rise to low-level or high-level 
phenotypic resistance (46). There are different molecular methods in clinical practice to 
identify resistance in M.tuberculosis; the Xpert MTB/RIF and LPA. The semi-automated 
Xpert MTB/RIF detects mutations in the genetic region rpoB (encoding RNA polymerase) 
linked with phenotypic resistance against rifampicin with high sensitivity and specificity 
(94% and 98% respectively) in under 2 hours directly from sputum samples, without 
requiring a biosafety laboratory (47). The improved Xpert MTB/RIF Ultra has a marked 
increased sensitivity; a 17% increased sensitivity for smear-negative patients and 13% 
increase for paucibacillary HIV patients and similar specificity compared to Xpert MTB/RIF. 
A related investigational assay with DST for major second-line drugs is being explored (48).  
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Rifampicin is commonly used as a marker of MDR-TB since simultaneous resistance to 
isoniazid is seen in more than 90% of cases (49). Moreover, WHO recommends MDR-TB 
treatment also for disease due to rifampicin mono-resistant isolates (50). GeneXpert is 
suitable in settings with a high prevalence of rifampicin resistance as well as for diagnostic 
purposes in low-endemic settings (51). 
LPAs are more labour-intense, requiring cultured M.tuberculosis as well as a TB-laboratory 
but can also detect resistance mutations for isoniazid, second-line injectable drugs and 
fluoroquinolones within 8 hours (52). LPAs show varying performance depending on drug; 
99% sensitivity for isoniazid and 85.6% for fluoroquinolones from indirect samples (53). 
Molecular methods can greatly speed up the detection of resistance, but they still show a 
relatively low negative predictive value for many drugs, such as pyrazinamide, as many 
resistance mutations are unknown (54, 55). Consequently, they should presently only be used 
to rule in, rather than rule out resistance.  
2.2.2.2 Whole genome sequencing – for mutation detection and strain identification  
Whole genome sequencing (WGS) is a method to establish the full nucleotide sequence of an 
organism’s DNA (i.e. genome) and can be used for TB diagnosis, mutation detection and 
strain identification for epidemiological purposes. The technique has been shown to shorten 
the average time to result from 3 weeks with conventional DST, to 9 days using WGS at a 
lower cost (56). However, WGS is only available in specialised centres and the relationship 
between mutations and phenotypic resistance is not completely known. For instance, about 
10% of phenotypically isoniazid resistant strains show no mutation in either katG or inhA, 
indicating mutations in other regions or alternative resistance mechanisms. Conversely, a 
mutation does not lead to resistance unless it is expressed. (30). Furthermore, it remains 
technically difficult to perform WGS directly from sputum samples, adding time for 
M.tuberculosis culture to the turn-around time of the method. Nevertheless, WGS has 
currently replaced phenotypic DST for isolates without resistance mutations in England and 
the Netherlands (57).  There are ongoing efforts supported by the Bill & Melinda Gates 
foundation to enable the interpretation of WGS data for TB in a comprehensive open-access 
database (58, 59), although smaller databases already exist (ReseqTB, TBResist etc). In a 
recent large study by the CRyPTIC consortium, susceptibility to first-line drugs could be 
correctly predicted by DNA sequencing (97.9% match) (60). 
2.2.2.3 Phenotypic drug susceptibility testing 
DST is traditionally performed on either an egg- or agar-based medium using one of three 
different methods; the critical concentration, resistance ratio and the proportion method. DST 
can be performed with direct (sputum) or indirect samples (cultured M.tuberculosis isolates) 
on solid (eg. LJ) or liquid media (eg. 7H9). The use of liquid media (7H9) has shortened the 
turnaround time for DST for pre-cultured isolates, from 3-4 weeks on solid media to 
approximately 1-2 weeks using liquid media with BACTEC MGIT 960 (61). 
The most commonly used method of susceptibility testing for M.tuberculosis is the 1% 
indirect agar proportion method, where the percentage of growth of a defined inoculum in a 
culture media containing the critical concentration of the drug is compared to growth in a 
drug-free control (45, 62, 63). Critical concentrations have only been defined for the indirect 
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proportion method. DST is typically performed in BACTEC MGIT 960 in resource-rich 
settings. DST of pyrazinamide is often not performed in many high-burden countries, due to 
the requirement of specialised, slightly acidic media during culture and problems with 
reproducibility and reliability (64).  
Table 2. Overview of phenotypic drug susceptibility testing in M.tuberculosis. Adapted 
from previously published review (65). 
Method Detection of growth 
Direct evidence Indirect evidence 
Critical 
concentrations 
Resistance ratio Nitrate reductase assay 
Absolute concentration Resazurin test 
MODS Alamar blue test 
Microtitre plates (e.g. Sensititre)  
Critical proportion 
and critical 
concentrations 
Löwenstein-Jenssen solid media BACTEC MGIT 960 (7H9) 
7H10 or 7H11 (CLSI protocol)  
MODS: Microscopy observed direct susceptibility testing, CLSI: Clinical and Laboratory Standards Institute, 
MGIT: Mycobacterial growth indicator tubes 
2.2.3 Minimum inhibitory concentrations – quantification of resistance  
The minimum inhibitory concentration (MIC) for tuberculosis is the lowest concentration that 
inhibits >99% or visible growth of a microorganism (liquid/solid media) (40). A range of 
concentrations in two-fold serially diluted steps are tested and the MIC values typically form 
a normally distributed curve. Although more time-consuming, the MIC provides a more 
descriptive level of resistance to the drug than other phenotypic DST methods.  
MIC determination can be performed on solid media, such as LJ or Middlebrook 7H10 and 
there is no reference method for MIC determination. More commonly liquid media, such as 
BACTEC MGIT 960, is used to reduce turn-around time. It is clinically important to be 
aware that MIC determination is associated with inter- and intra-laboratory variability (66).  
Recently, prefilled broth-based microtitre plates with freeze-dried antibiotics have enabled 
simultaneous MIC determination of 12-14 first- and second-line drugs. Mycobacterial 
suspensions are inoculated in the 96-well plate, incubated and read after 10-21 days (67). The 
advantages of the microtitre plate are reduced cost when testing multiple drugs compared to 
BCTEC MGIT, as well as it being less labour-intensive. The disadvantages are manual 
reading with truncated MICs and the need of a BSL 3 laboratory, decreasing its feasibility in 
resource-limited settings. Furthermore, MIC testing of pyrazinamide is not yet possible in 
microtitre plates. To date, there are no defined critical concentrations for microtitre plates 
(67). Critical concentrations for the agar proportion method on solid culture media have been 
suggested for the Sensititre plate but need validation (68).  
Knowledge of bacterial resistance (DST/MIC) is instrumental to guide management of 
individual patients.  
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2.3 TREATMENT OF TB - RECOMMENDED DOSES AND DURATION UNDER 
REVISION 
The current recommended drug regimen of TB is under scrutiny, especially the dose of 
rifampicin, but also levofloxacin and pyrazinamide (NCT01918397) (69). In the 1960s, the 
dose was selected due to fear of toxicity but also due to costs; for example, one week of 
monotherapy with rifampicin was equivalent in cost to the whole six-month treatment of 
today (70). There is evidence of subtherapeutic blood levels of rifampicin mainly from high-
endemic countries, whereas fewer studies have been performed in low-endemic settings with 
high-quality drugs.  
The treatment length of TB should ideally be shortened to reduce costs, side effects, drug 
burden and risk of resistance developing. Unfortunately, four clinical trials have failed to 
show support for a shortened four month therapy through the addition of a fluoroquinolones 
(71-74). The cure rate of susceptible TB in Sweden is similar to the global success rate of 
82% reported by WHO (4, 35). Relapse of TB after successful treatment is seen in less than 
1-2% of patients in high-resource settings (35, 75). Failure of TB treatment is multifactorial, 
but it is important to exclude acquired resistance. A vital paradigm in TB treatment is never 
to add a single drug to a failing therapy to avoid further resistance to develop. A repeat DST 
should always be performed if clinical improvement is slow.  
2.4 TREATMENT OF MDR-TB – OPTIMIZATION URGENTLY NEEDED 
MDR-TB is difficult to treat, requiring longer treatment durations due to less efficacious 
drugs, and is associated with increased cost, adverse events and poor treatment outcome. To 
enable the programmatic treatment of MDR-TB, especially at a lower health system level, a 
standardised MDR-TB treatment is common, although WHO also supports an individualised 
treatment, guided by DST and contact history (50).  
Unfortunately, treatment outcome of MDR-TB and especially XDR-TB is approaching the 
pre-antibiotic era, as the success rate of XDR-TB in Europe 2016 was 33.8% (cohort from 
2013) (76) and a global cure rate of 55% of MDR-TB (4). However, there is hope for 
improved cure rates with the long-awaited addition of two new highly effective drugs; 
bedaquiline and delamanid (Table 3).   
Table 3. New approved antituberculosis drugs. 
Generic name Brand name Chemical 
class 
Mechanism of action on 
M.tuberculosis 
Bedaquiline Sirturo Diarylquinoline Inhibits energy metabolism by 
blocking ATP-synthase 
Delamanid Deltyba Nitroimidazole Inhibits cell wall by blocking the 
synthesis of mycolic acids 
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The use of one of the two additional drugs, bedaquiline, has recently been upgraded in the 
newly revised WHO treatment recommendations of MDR-TB, forming an all oral 
background regimen treatment with a fluoroquinolone and linezolid (77). The basis of this 
change partly stems from a recent individual patient meta-analysis with 12 030 patients 
included in studies from 2009-2016, where more than 61% had a successful treatment 
outcome. The optimal number of drugs were found to be five in the initial phase and four in 
the continuation phase, with the mean optimal treatment duration being 21 months (78).   
 
Table 4. Recommended drugs for MDR-TB treatment – 2018 WHO update 
Group Drug Mechanism of 
action 
Adverse drug reaction 
A 
(include all if 
possible) 
Moxifloxacin/ 
Levofloxacin 
Inhibits DNA gyrase Arthralgia, achilles 
tendon rupture 
Bedaquiline Inhibits DNA 
synthase  
QT-prolongation, liver 
toxicity 
Linezolid Inhibits protein 
synthesis 
Pancytopenia, 
polyneuropathy 
B 
(add both if 
possible) 
Clofazimine Phenazine die, interfering with DNA 
synthesis 
Reversible skin 
discolouration  
Cycloserine OR 
Therizidone 
Prevents cell wall 
synthesis 
Neurotoxicity, 
psychiatric 
disturbances, 
neuropathy 
C 
add when drugs 
from Group A and 
B cannot be 
used) 
Ethambutol, Delamanid, Pyrazinamide, Imipenem-cilastatin OR   
Meropenem/clavulanic acid, Amikacin, Ethionamide/Prothionamide, 
p-aminosalicylic acid 
 
Adverse drug reactions caused by second-line drugs are very common, as high as 79% in 
previous studies (79). A Cochrane review revealed that as many as 16-49% of patients with 
MDR-TB fail to complete treatment (80). Hopefully, this will change with the newly 
recommended and entirely oral treatment, although adverse drug reactions are frequently seen 
with long-term use of linezolid and monitoring is difficult in high-endemic settings (81).  
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2.4.1 Shortened treatment of MDR-TB with more drugs – the MDR-TB short 
course 
Ideally, MDR-TB treatment should be a short and completely oral regimen. The so-called 
Bangladesh regimen for MDR-TB consists of a 9-month treatment course with an initial 
regimen of seven anti-TB drugs, kanamycin, moxifloxacin, prothionamide, clofazimine, 
pyrazinamide, high-dose isoniazid and ethambutol for 4-6 months, followed by five months 
of moxifloxacin, clofazimine, pyrazinamide and ethambutol. This regimen attained a 
treatment success rate of more than 85% and with very few relapses in the two-year follow-
up period (82). A slightly higher treatment success rate (89%) was seen in a 12-month MDR-
TB regimen in Cameroon, although as many as 43% of the patients suffered from hearing 
impairment due to treatment with kanamycin (83). The MDR-TB short course regimen was 
endorsed in 2016 by WHO, although its use has been questioned in some settings due to 
widespread resistance to included drugs, such as pyrazinamide and ethambutol (84).  
Interim data from the STREAM I trial evaluating the short-course regimen showed successful 
treatment outcome in 78.1% versus 80.6% using standard WHO MDR-TB treatment of 20-24 
months (85), although non-inferiority has not yet been shown (86). The STREAM II trial is 
evaluating three short course regimens compared to standard MDR-TB treatment. Two of the 
regimens contain bedaquiline, of which one is all oral, which would greatly simplify 
treatment (NCT02409290). 
2.4.2 Repurposed drugs – an untapped potential? 
Evidence of resistance was seen not long after the introduction of bedaquiline and delamanid 
(87) and there are contraindications such as QTc-prolongation with risk of ventricular 
arrhythmias (both drugs) or hypoalbuminemia (delamanid) restricting their use. Alternative 
drugs are always needed, which is why the use of already approved drugs is being 
investigated (69). Repurposed drugs are drugs with activity against diseases other than they 
were originally intended for. An examples of a repurposed drug is linezolid, used for 
treatment of gram-positive infections. In vitro studies have shown anti-TB activity of 
trimethoprim-sulfamethoxazole (TMP-SMX), meropenem-clavulanic acid (MEM-CLA) as 
well as imipenem-cilastatin (88-90). However, the majority of these studies are performed on 
susceptible isolates and rarely include clinical MDR-TB strains. Moreover, there are no 
clinical trials evaluating the effect in vivo of these drugs. 
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2.4.3 Surrogate markers of treatment outcome and clinical improvement of 
TB used in trials and clinical practice.  
In order to evaluate new drugs or drug regimens for TB, surrogate markers such as sputum 
culture conversion and changes in bacterial sputum load are often used. However, short 
duration trials are intrinsically limited in predicting the final treatment outcome (91) and valid 
biomarkers predicting treatment outcome are of importance. 
2.4.3.1 Sputum culture conversion 
Time to sputum culture conversion or sputum culture conversion after two months of 
treatment is commonly used to evaluate treatment effect in drug trials (92). However, the 
supporting evidence is weak and studies have shown sputum culture conversion to be an 
imperfect predictor of the final treatment outcome (93, 94), which is problematic for TB drug 
development. A systematic meta-analysis, treatment evaluation with sputum-smear 
microscopy and/or mycobacterial culture after two months of treatment showed low 
sensitivity and modest specificity for predicting failure and relapse of susceptible TB. The 
negative predictive value (93%) was substantially higher than the positive predictive value of 
sputum culture conversion (9-18%), meaning that a negative sputum culture at month two 
makes relapse and failure unlikely. However, a positive sputum culture at month 2 could not 
predict relapse and failure (95). Similar results have been shown for MDR-TB, where culture 
conversion at month 2 of treatment had a sensitivity of 27.3% (95% CI 16.6-41.4) in 
predicting successful treatment outcome (vs failure/death) in a study with 1712 patients. 
Sputum culture conversion at month 6 had a higher sensitivity (91.8%, 95% CI 85.9%-
95.4%) but lower specificity (57.8%,95% CI 42.5%-71.6%) (96). 
2.4.3.2 Time to positive culture (TTP) and early bactericidal activity (EBA) 
Early bactericidal activity (EBA) assesses the fall in colony forming units (CFU) on agar 
plates and is a measure of the bacterial burden. Daily sputum samples from smear-positive 
TB patients taking a particular drug is traditionally used to evaluate drug efficacy in TB 
treatment trials (97). However, EBA only assesses the initial phase of bacterial kill, as 
exemplified by clofazimine which has no effect on the EBA the first 14 days (98). Liquid 
media has higher sensitivity for mycobacterial growth (99) and time to culture positivity 
(TTP) in BACTEC MGIT 960 has been shown to be a useful alternative for assessment of 
drug efficacy (100, 101). TTP data can be easily accessed from the BACTEC MGIT 960. 
2.4.3.3 Clinical severity scores – TBscore & TBscore II 
Clinical severity scores, to increase case-finding and to predict treatment outcome, has been 
developed for TB. The TBscore II is a simplified version of the original TB-score, where 
physical examination of a physician was required. The variables included in TBscore II are 
cough, dyspnoea, chest pain, anaemia, body mass index (BMI) <18 and <16, mid upper arm 
circumference (MUAC) <220 mm and <200 mm. TBscore II has been validated in two high-
burden cohorts (Ethiopia and Guinea-Bissau). A decrease of less than 25% of TBscore II 
from baseline to two months of treatment was associated with subsequent treatment failure in 
Guinea-Bissau (p=0.007) (102), but not in Ethiopia. Today, there is no clinical validation of 
the TB-score or other clinical scoring systems in low-endemic settings.   
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2.5 PHARMACOKINETICS AND PHARMACODYNAMICS 
Pharmacokinetics (PK) and pharmacodynamics (PD) describe the interactions of drug and 
body. 
2.5.1 Pharmacokinetics 
The PK of a drug describe what the body does with the drug, i.e. how the drug is absorbed, 
distributed and cleared from the body. The changes of drug concentrations in the body over 
time are commonly summarised with the measures absorption (F), volume of distribution (V) 
and elimination (CL) (Table 5) (103). 
Table 5. Definitions of key pharmacokinetic measures. 
Absorption A Bioavailability, the unchanged fraction from 0-1 
(0-100%) of the administered dose that reaches the 
circulation. Large, hydrophilic drugs are poorly 
absorbed as opposed to small, lipophilic drugs. 
First-pass metabolism by the liver might also lower 
the bioavailability.  
Volume of distribution Vd The apparent volume that the drug is distributed in, 
relating the administered dose to the plasma 
concentration. The volume might be over 10 000 L 
(extensive tissue distribution). The volume of 
distribution is affected by protein binding where 
high protein binding gives a low V.  
Clearance 
CL= V / k 
k= constant 
CL= rate of elimination / C 
CL The rate of drug elimination divided by the plasma 
concentration of the drug i.e. the volume of fluid 
cleared each unit of time (eg. L/h). The clearance 
determines the plasma concentration at steady 
state, i.e. the Caverage. The renal clearance is 
decreased in case of acute renal failure.  
2.5.2 How is pharmacokinetics of drugs studied? 
In order to estimate the Cmax and the AUC, multiple blood samples are needed. Only a few 
patients are needed in a so called rich-sampling scheme, with multiple blood tests from the 
time of the first dose and repeatedly thereafter. The AUC can then be calculated, using the 
trapezoidal method, where the area under the curve is divided into smaller trapeziums, so that 
the areas can be calculated and totalled. The fewer the samples, the less reliable is the 
estimation of the AUC. In order to study more patients, a limited sampling strategy, where 
two or three blood samples are enough to estimate the AUC, has been developed for many 
TB-drugs (104). Multiple samples are also needed to estimate the Cmax, since delayed 
absorption might lead to a delayed peak in drug concentration.   
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It is the free, unbound concentration in plasma that is the active component of the drug (103) . 
The total drug concentration of the drug can be measured and the free ( f ) drug concentration 
can be estimated by multiplying with known constants of protein binding, if the free 
concentration is not measured directly in the plasma.  
2.5.3 Pharmacodynamics 
The PD of a drug describe what the drug does to the body, i.e. the effect the drug exposure 
has on the body or on the bacteria. This could be pain relief or microbial killing, for example.  
2.5.4 PK/PD relationships 
By investigating the relationship between the two parameters PK and PD, the optimal dose of 
a drug can be estimated, balancing effect and toxicity.  
Firstly, the PK/PD relationship best describing the drug effect needs to be established and can 
be either concentration-dependent (Cmax, AUC/MIC) or time-dependent (%T>MIC). There is 
often a close relationship between the PK/PD indices Cmax/MIC and AUC/MIC. The optimal 
PK/PD index associated with best clinical outcome and suppression of drug resistance is then 
established. 
Figure 5. Schematic illustration of the area under the concentration versus time curve 
(AUC), maximal concentration (Cmax) and minimum inhibitory concentration (MIC). 
 
2.5.5 Pharmacometric modeling 
“…all models are wrong, but some are useful.” George E.P. Box 1987 
Pharmacometry is a multi-disciplinary field where pharmacology, statistics, mathematics and 
physiology meet. By pharmacometric modelling, predictions of a drug’s PK and PD 
characteristics can be made in a population, which is useful in assessing which dose will 
probably result in a desired outcome. Monte Carlo simulation is an example of a model useful 
for dose selection and breakpoint determination. Here, known PK parameters from the target 
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group are randomly selected, following the known standard deviation of a population and the 
responses of approximately 10 000 patients are then simulated, thus reducing the number of 
patients actually needed to be studied. The probability of target attainment (PTA) can also be 
calculated, i.e. the probability of achieving a certain PK/PD goal following Monte Carlo 
simulation for given MIC-values. The cumulative fraction response (CFR) calculates a PTA, 
while taking the local MIC distribution into account, and may vary between settings (105). 
A clinical application of PK/PD and pharmacometry is therapeutic drug monitoring (TDM). 
2.6 THERAPEUTIC DRUG MONITORING (TDM) – INTEGRATING 
INTERACTIONS OF HOST, PATHOGEN AND DRUG 
The over-arching aim of TDM is to improve treatment outcome and reduce toxicity and 
adverse drug reactions. TDM involves measuring drug blood concentrations and adjusting 
dosages in order to optimise therapy and reduce adverse-effects. TDM integrates the 
concentration and the effect of a drug while taking the efficacy of drug and patient toxicity 
into account. Since the 1970s, TDM has been used to individualise therapy in many areas of 
medicine, such as immunosuppressant drugs. Monitoring of drug concentrations is especially 
important where there is a narrow therapeutic window (for example aminoglycosides) or 
when there is substantial inter-individual variation. The lowest drug concentration ensuring 
efficacy, and the highest drug concentration while avoiding toxicity, are defined for each 
drug. What differs with the use of TDM in infectious diseases is that the level of bacterial 
resistance affects the efficacy and might vary between different infected individuals. 
Therefore, the level of resistance of the bacteria should also be assessed.  
Figure 6. Therapeutic drug monitoring (TDM) - taking drug exposure and bacterial level of 
resistance (minimum inhibitory concentration, MIC) into account to improve treatment 
outcome.
 
Illustration by Moi Peña 2018  
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2.6.1 Therapeutic drug monitoring in TB 
Drug exposure of TB-drugs is greatly influence by multiple factors such as concomitant food 
intake, comorbidities, malabsorption, drug-drug interactions and pharmacogenetics (104). 
Pharmacogenetics describes how genetics influences the response to a drug. For example, 
polymorphism genes encoding for metabolizing proteins will result in variable drug exposure 
between patients (101), for example isoniazid (101). 
Low drug concentrations of TB drugs in blood in clinical settings have frequently been seen, 
although the majority of studies are from high-endemic areas (105). The drug exposure of 
recommended doses of first-line drugs in TB-patients in Sweden is unknown. Rifampicin is a 
particularly unpredictable concerning dose and drug exposure, due to variability in absorption 
as a result of genetic polymorphism as well as enhanced clearance after repeated doses owing 
to autoinduction of hepatic enzymes and increased pre-hepatic first-pass metabolism (106). 
Furthermore, the non-linear kinetics of rifampicin due to saturable biliary excretion and 
exposure-dependent bioavailability means a dose increase might result in a more than 
proportional increase in the drug exposure (107, 108). The recommended ranges of the first-
line TB drugs are based on early pharmacokinetic studies in healthy volunteers and TB 
patients on treatment, often lacking correlation with treatment outcome (109, 110). 
The plasma drug concentration might not reflect the concentrations at the site of infection, 
depending on the drug’s pharmacodynamic characteristics. The recommendations above do 
not take clinical variables into account, such as concomitant HIV infection, the bacterial MIC 
or the site of infection. It should also be noted that a prerequisite for TDM is a clearly defined 
relationship between plasma concentrations and bacterial killing in TB patients, which has 
not yet been defined for all TB-drugs (111, 112). There is a need to define the optimal drug 
exposure, also in relation to the bacterial resistance, since the PK/PD target is unknown for 
many drugs. Despite knowledge gaps, TDM for TB is endorsed by many experts, including 
the American Society of Infectious Diseases and the European Respiratory Society and is 
used clinically in many settings. 
In a systematic meta-analysis, there was no evidence to support the use of TDM as routine 
care for susceptible TB (105). Drug concentrations were frequently low, but only linked to 
treatment outcome in three out of 12 studies evaluating treatment outcome. However, there 
was heterogeneity in the number of blood samples collected and a relative uncertainty of the 
estimation of Cmax and AUC. An overview of PK/PD studies including outcome measures 
regarding first- and second-line drugs are presented in Table 6.  
2.6.2 New treatment strategies for MDR-TB needed 
Despite progress and bold goals to combat TB, there remains substantial impoverishment, 
death and suffering caused by TB around the world. In summary, new tools for treatment 
improvement of TB and MDR-TB are urgently needed, such as new drugs or methods for 
personalized medicine in the field of TB. 
. 
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Table 6. Clinical studies reporting drug exposure in relation to clinical outcome measure. A PubMed search with search-terms “Therapeutic drug 
monitoring” OR TDM OR PK/PK OR “Pharmacodynamics/pharmacokinetics” OR Concentrations) AND (Outcome OR Treatment OR Conversion OR 
Success OR Fail OR Failure) AND (Rifampicin OR Isoniazid OR Ethambutol OR Pyrazinamide) AND (Tuberculosis) was performed (July 2018) found 
146 studies, of which 23 reported an outcome measure (bacteriological or treatment outcome) for adults with drug-susceptible TB. Studies comprising 
adult patients, with an aim to assess drug exposure or dose increase in association with an outcome measure (bacteriological or treatment outcome) for 
(RIF/R), isoniazid (INH/H), pyrazinamide (PZA/Z) and/or ethambutol (EMB/E) on daily treatment were included. Asterix (*) highlights studies where drug 
concentrations correlated to the outcome measure (11 out of 23 studies). 
Author Drug/doses Study design No. of 
patients 
Sampling 
post dose  
Exposure Outcome 
measure 
Results 
Velasquez 
2018 (106) 
Peru   
“HIGHRIF I” 
RIF 10, 15 and 
20 mg/kg for 8 
weeks + HZE 
RCT phase II 
 
180 PTB  
(5 HIV+) 
120 patients: 0, 
2, 6 h          60 
patients: 0, 0.5, 
1, 1.5, 2, 6, 14 
h 
Dose mg/kg, 
AUC0-6 and 
AUC0-6/MIC 
Change in 
log10 CFU 
and SCC at 
week 8. 
No difference in SCC at week 8. Increased 
rate of CFU decline for the higher RIF dose. 
AUC and AUC/MIC not related to outcome.  
Aarnoutse 
2017 (107) 
Tanzania 
“HIGHRIF II” 
RIF 600mg, 900 
and 1200 mg + 
HZE 
RCT phase II 63 TB  
(15 HIV+) 
Eleven 
samples from 
0-24 h at week 
6 
RIF AUC, Cmax 
& dose 
tSCC No difference in bacteriological response; 
not powered for small differences 
Alkabab 2017 
(108)          
USA 
Standard doses 
HRZE 
Retrospective 
cohort, 
matched 
363 PTB 
(pre/post-
intervention, 
DM 56) 
2 h at week 2 TDM RIF & 
INH as 
intervention 
(dose 
adjustment) 
tSCC and 
SCC at 
month 2 
*Significantly shorter tSCC for post-
intervention group (-8 days) and -20 days for 
DM- compared to DM+ patients. Reduced 
tSCC at month 2 for post-intervention group 
Boeree 2017 
(109) 
Tanzania & 
South Africa 
RIF 10 mg/kg, 
20 mg/kg, 35 
mg/kg +/- MFX 
+ HZE  
RCT phase 2      
(SQ109  
stopped) 
365 PTB 
(24 HIV+) 
NA Increased dose 
without PK 
measured 
tSCC in 
liquid and 
solid media 
*tSCC was significantly quicker in 35 mg/kg 
vs control group (median 48 vs 62 days) but 
not in the other arms. No difference in tSCC 
on solid media. 
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Rockwood 
2017 (110) 
South Africa 
Standard doses 
HRZE 
Prospective 
observational 
cohort study 
100 PTB  
(65 HIV+) 
0, 2, 3, 4, 6, 8h 
at week 8 
AUC/MIC and 
Cmax/MIC of 
RIF, INH, PZA 
SCC and 
treatment 
outcome 
*Low drug concentrations for RIF 80%, INH 
43% and PZA 53%. PZA <35 mg/L 
predictive of failure/relapse. Concentration-
dependent antagonism at low RIF and INH 
concentrations for SCC at month 2. 
Heemskerk 
2016 (111) 
Vietnam 
RIF 15 
mg/kg+LFX 20 
mg/kg + 
standard HZE 
RCT TB 
meningitis 
(349 HIV+) 
NA Intensified 
treatment vs 
standard 
treatment 
9 months: 
death and 
neurologic 
disability  
No significant effect of the intensified 
treatment  
Maze 2016 
(112) 
New Zealand 
Standard doses 
HRZE  
Retrospective 
cohort study 
121 TB  2 h High vs low C2h 
RIF & INH 
tSCC and 
treatment 
outcome 
Low RIF and INH concentrations (35 
patients) were neither associated with 
successful treatment outcome nor tSCC. 
Dose adjustments might have contributed to 
the favourable outcome. 
Boere 2015 
(113)      
South Africa       
HIRIF I 
RIF 10mg/kg vs 
RIF 15, 20, 25, 
30 mg/kg for 
2w+HZE 
RCT phase II 68 PTB 
patients         
(1 HIV+) 
Rich-sampling 
PK curve 
PK of RIF Fall in CFU 
and TTP in 
sputum 
samples 
*There was a greater estimated fall in 
sputum bacterial load in the higher dosing 
groups 
Chigutsa 
2015 (114) 
South Africa 
Standard doses 
(FDC) HRZE 
Subset of a 
clinical trial 
54 PTB  
(7 HIV+) 
4-8 samples 
during 0-7 h  
AUC, Cmax,  
AUC/MIC, 
Cmax/MIC,  MIC 
Fall in TTP 
and SCC at 
month 2. 
*Low Cmax for RIF (<8.2mg/L) and low 
AUC/MIC (<11.3mg*h/L) associated with 
slower bacterial elimination. RIF Cmax <8.2 
mg/L associated with a lower proportion of 
SCC at month 2 
Mah 2015 
(115) 
Canada 
Standard doses  
HRZE 
Retrospective 
cohort study 
134 PTB   
(33 HIV +)  
2, 6 h Cmax of RIF & 
INH 
SCC month 
2 and 
treatment 
outcome 
*Low concentrations of INH associated with 
a positive sputum culture at month 2 (OR 
3.3 95CI 1.33–8.33), similar but non-
significant results for RIF. No association 
with the final treatment outcome. 
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Meloni 2015 
(116) 
Switzerland 
Standard doses 
HRZE 
Retrospective 
cohort study 
17 TB (7 
HIV+) 
2, 4, 6 h Cmax of RIF, 
INH, PZA, 
EMB & RIB 
Treatment 
outcome 
16 of 17 patients had at least one drug with 
low concentration and 94% were cured. 
Dose adjustment was performed. 
Park 2015 
(117) 
South Korea 
Standard doses 
HRZE 
Retrospective 
cohort study 
413 TB  2 h C2h of RIF, 
INH, PZA, 
EMB 
SCC 2m + 
treatment 
outcome 
Low concentrations had no association with 
SCC or treatment outcome. Dose 
adjustment was performed for a >50%. 
Prahl 2014 
(118) 
Denmark 
Standard doses 
HRZE 
Prospective 
observational  
32 TB 
(2 HIV+)  
2 h C2h of RIF, 
INH, PZA, 
EMB 
Treatment 
outcome 
(death/relap
se)  
*Low concentrations of INH (71%), RIF 
(58%), EMB (46%) and PZA (10%).  Low 
drug concentrations of both RIF and INH 
associated with therapy failure (5 patients) 
Burhan 2013 
(119) 
Indonesia 
Standard doses 
HRZE 
Prospective 
cohort study 
181 PTB 
(2 HIV+) 
2 h C2h RIF, INH & 
PZA 
SCC at 
month 2 
91% had one drug (RIF, INH, PZA) lower 
than recommended. Drug concentrations 
were not associated with SCC at month 2.  
Van 
Tongeren 
2013 (120)  
Standard doses 
HRZE 
Retrospective 
cohort study 
52 TB 
(12 HIV+) 
2 h C2h RIF & INH Acquired 
drug 
resistance 
*Low drug concentrations frequent; INH 
(76.6%, associated with male sex) and RIF 
(68.4%). Five patients with low drug 
exposure showed acquired drug resistance. 
Dose adjustments were made.  
Pasipanodya 
2013 (121) 
South Africa 
Standard doses 
HRZE 
 
Prospective 
cohort 
study(severe 
cases) 
142 PTB  
(15 HIV+) 
0, 0.5, 1, 1.5, 
2, 2.5, 3, 4, 6, 
8 h at month 2 
Cmax and AUC 
for RIF, INH & 
PZA 
SCC and 
treatment 
outcome 
*Significant association with treatment 
outcome; PZA AUC0-24h ≤ 363mg*h/L, RIF 
AUC0-24h ≤13mg*h/L & INH AUC0-24h ≤ 
52mg*h/L and with SCC month 2; PZA Cmax 
≤58.3, RIF Cmax ≤6.6 and INH Cmax≤ 8.8  
Ruslami 2013 
(122) 
Indonesia 
 
 
Standard RIF 10 
mg/kg vs iv RIF 
13 mg/kg + HZE 
RCT phase 2 50 
TB-
meningitis 
0, 1, 2, 4, 6 
and 24 h at 
day 3 
PK and Cmax of 
RIF, EMB, PZA 
Mortality 6 
months 
after start 
*Mortality reduction by 50% with intravenous 
increased dose of RIF, no added benefit of 
MFX. 
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Requena-
Méndez A 
2012 (123) 
Peru 
Standard dose 
HRZE 
Cross-sectional 
observational 
study 
105 TB 
patients (26 
DM+, 29 
HIV) 
2, 6 h Cmax of RIF PK RIF, 
DM, HIV +/- 
& treatment 
outcome 
No effect of DM or HIV on RIF 
concentrations. Out of five patients with poor 
treatment outcome, four had low drug 
exposure. 
Chideay 2009 
(124) 
Bostwana 
Standard doses 
of HRZE 
Prospective 
cohort study 
225 PTB  
(155 HIV+) 
1, 2, 6h Cmax and AUC 
of HRZE 
Treatment 
outcome 
*Low drug concentrations were frequent; 
(RIF 84%, INH 37%, EMB 39% and PZA 
5%) and associated with HIV. Low PZA 
exposure associated with poor treatment 
outcome.  
Chang 2008 
(125) 
Hongkong 
Standard doses 
HRZE 
Case-control 
study 
 
74 PTB 2, 4 h  Cmax RIF  SCC at 
month 2  
 
No association between RIF Cmax and SCC. 
Controls were patients with SCC at month 2 
and cases patients with no SCC at month 2 
Ruslami 2007 
(126) 
Indonesia 
10 vs 13 mg/kg 
of RIF + HZE for 
6 months 
RCT phase II 50 PTB (1 
HIV +) 
0, 1, 1.5, 2.5, 
3, 4, 6 and 12 
h at week 6. 
AUC and Cmax 
of RIF 
SCC and 
treatment 
outcome 
No difference in SCC and treatment 
outcome, although not powered to assess. 
Van Crevel 
2002 (127) 
Indonesia 
Standard doses 
HRZE 
Prospective, 
observational 
62 (1 HIV+) 2 h C2h of RIF Treatment 
outcome 
70% had very low (<4 mg/L) of C2h , no 
difference in treatment outcome was seen. 
The strongest predictor of drug exposure 
was drug manufacturer (bioavailability) 
Narita 2001 
(128)         
USA 
Standard doses 
HRZE 
Retrospective, 
cohort study 
188 (69 
HIV+) 
2 and 6 h at 
week 2 
Cmax RIF and 
INH 
Recurrent 
TB 
Recurrence of TB was not associated with 
low drug levels or HIV infection. 
CFU: colony-forming units, DM: Diabetes Mellitus, E: ethambutol, FDC: Fixed dose combination, HIV: Human immunodeficiency virus, H: isoniazid, LFX: levofloxacin 
MFX: moxifloxacin, NA: not applicable, p: patients, PTB: pulmonary TB, R: rifampicin RCT: Randomised controlled trial, standard doses: according to WHO 
recommendations, tSCC: time to sputum culture conversion, TTP: time to positivity in liquid culture, Z: PZA
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3 AIMS 
3.1 OVERALL AIM OF THE THESIS 
 
The aim of this thesis is to explore different approaches to combat MDR-TB, such as 
repurposing drugs, elucidating the importance of the level of drug resistance of TB-drugs as 
well as the role of therapeutic drug monitoring in the treatment of MDR-TB. 
3.2  SPECIFIC AIMS OF THE INCLUDED STUDIES 
 
 To determine the effect of TMP-SMX and MEM-CLA on susceptible and drug-
resistant M.tuberculosis (Study I&II).  
 
 To study the importance of individual mycobacterial MIC and its association with 
sputum culture conversion and treatment outcome in MDR-TB (Study III) 
 
 To investigate individual drug exposure (Cmax & AUC) in drug-susceptible TB-
patients and the corresponding mycobacterial MIC (Study IV) 
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4 MATERIAL AND METHODS 
An overview of methods is presented below. More detailed information is found in the 
respective articles.  
4.1 MATERIAL / STUDY DESIGN AND SETTINGS 
4.1.1 Studies I & II  
Unique M. tuberculosis isolates were studied, consisting mainly of MDR/XDR-TB isolates, 
including clinical isolates from patients from different continents, and isolates submitted to 
the supranational reference TB-laboratory at the Public Health Agency of Sweden for 
proficiency DST. The pan-susceptible strain H37Rv (ATCC 27294) was used as control. 
4.1.2 Study III 
Due to mandatory reporting of TB, the Swedish national TB registry offers full-coverage of 
all diagnosed cases in Sweden. In this retrospective cohort study, all MDR-TB cases 
diagnosed in Sweden 1992-2014 were included (n=163). Five medical records had been lost, 
leaving 158 patients for analysis. Data were collected concerning sociodemographic 
information (i.e.  gender, age, country of origin, years in Sweden, asylum status, use of 
interpreter), clinical characteristics (smoking, alcohol/drug use, height, weight, comorbidities, 
radiology reports, treatment regimens and duration, adverse drug reactions, tSCC, treatment 
outcome and microbiological data including routine DST). A treatment duration of one 
month or longer was defined as having received treatment with that drug. The MDR-TB 
diagnosis was phenotypically confirmed at the TB-laboratory of the Public Health Agency of 
Sweden, a national and supranational reference laboratory. 
4.1.3  Study IV 
In this prospective cohort study, patients with active, fully susceptible TB at Karolinska 
University Hospital Solna and Linköping University Hospital in Sweden were consecutively 
included from October 2012 until December 2014. Patients with MDR- or XDR-TB, ongoing 
infection other than HIV or unable to give informed consent, were excluded from the study.  
Plasma concentrations of all first-line drugs were measured after two weeks of TB treatment 
as well as after four and 12 weeks of treatment. The drug exposure was then compared to the 
individual mycobacterial MICs. The final treatment outcome was retrieved from the national 
TB registry and compared to the medical records.  
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Figure 7. Overview of study design of Study IV. 
 
 
4.2 METHODS OF DRUG SUSCEPTIBILITY TESTING (DST)  
The proportion method is the reference method for DST for M.tuberculosis. The growth of a 
standardised bacterial inoculum on a drug-free medium is compared with the growth on 
medium containing the critical concentration of a drug. A 1% critical proportion is used to 
define resistance to TB-drugs (apart from 10% for pyrazinamide) (40). Potential sources of 
error include bacterial inoculum standardisation, drug-containing suspension, media pH, 
incubation time and temperature as well as the validity of the critical concentration (129).  
4.2.1 Solid LJ media – Study III 
Solid media using LJ was used for DST testing of cycloserine and PAS in Study III. 
Bacterial suspensions, calibrated to McFarland 0.5, are inoculated in drug-containing LJ 
media. A diluted bacterial suspension (1/100) is added to a growth-control slant incubated at 
37ºC. Resistance is defined as growth in the drug-containing slant exceeding the growth in 
the control tube, with at least 30-100 visible colonies. Growth is evaluated at week four, 
where resistance is evident, and at week six for susceptible isolates (63). The drug-containing 
media is often prepared locally, with risk of variable quality.  
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4.2.2 BACTEC 460 TB and BACTEC MGIT 960 – Study III & IV 
The older BACTEC 460 TB used radioactively-labelled tubes and measured CO2 production, 
whereas BACTEC MIGIT 960 detects oxygen consumption due to metabolic activity. 
Fluorescent material is embedded at the bottom of the MGIT tubes and the consumption of 
oxygen releases fluorescence which can be detected. Pre-manufactured MGIT tubes 
containing the critical concentration for the first-line drugs are commercially available, 
increasing the quality of the result but also costs. The tubes are incubated in BACTEC MGIT 
960 until a level of 400 Grown Unit (GU) for the control tube is detected and the tubes are 
read. The growth of the tube containing the critical concentration of the drugs is compared to 
the growth of the 1:100 diluted drug-free control tube. More growth (>100 GU) at a critical 
concentration compared to the 1:100 diluted control is regarded as resistance (130).  
Table 7. Critical concentrations used for first-line drugs and important second-line 
drugs in BACTEC MGIT 960 in Study III.    
 
Drug mg/L 
Rifampicin 1 
Isoniazid 0.1, 0.4 
Pyrazinamide 100 
Ethambutol 5 
Ofloxacin 2 
Amikacin 1 
 
4.2.3 Drug susceptibility testing of pyrazinamide - Study III & IV 
Susceptibility testing of pyrazinamide is pH-dependent (28) and liquid broth with a low pH of 
6.9 is used. However, the low pH itself inhibits the growth of M.tuberculosis isolates (28), 
which is why a bacterial suspension of 1:10, instead of the traditional 1:100, is used as 
growth control according to manufacturer instruction. The most common source of error in 
pyrazinamide DST is the inoculum size, where an excessively large inoculum will increase 
the pH and might lead to false resistance (64). Measures to decrease the risk are to sonicate 
the inoculum to homogenize the solution and to use fresh M.tuberculosis isolates, no older 
than two weeks (131). The McFarland turbidity is performed manually which is a potential 
source of error.  
4.3 MINIMAL INHIBITORY CONCENTRATIONS – SOLID, LIQUID OR 
MICROTITRE METHODS 
4.3.1 Solid media Middlebrook 7H10 - Study I & II 
Enriched Middlebrook 7H10 agar (Becton Dickinson AB, Stockholm, Sweden) was casted 
into 14-cm petri dishes. Serially diluted stock solutions of TMP-SMP and MEM-CLA were 
added (final ranges 0.008-8/0.15-152 TMP-SMX and 0.002-512 MEM with CLA 64 mg/L 
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added uniformly). A 96-stick replicator (Figure 8) was used to transfer bacterial inoculums to 
the plates, in order to enable simultaneous testing of a large number of isolates. The pan- 
susceptible M.tuberculosis strain H37Rv was used as a control in all dishes and the MIC was 
defined as the lowest concentration with less growth than the 1:100 diluted control, thereby 
representing > 99% inhibition. 
Figure 8. A 96-stick replicator used to inoculate agar plates. 
 
4.3.2 Intracellular versus extracellular MIC testing – Study I 
An H37Rv strain carrying the gene Vibrio harveyi luciferase was used and incorporated in a 
macrophage model for determining intracellular MIC. Luminescence is emitted by Vibrio 
harveyi luciferase only in the presence of living bacteria and the intracellular growth of 
M.tuberculosis was estimated by recording luminescence.  
4.3.3 MIC testing using BACTEC MGIT 960 - Study I, III & IV 
In MGIT tubes, serial 2-fold dilutions of antibiotics were added and incubated in BACTEC 
MGIT 960 according to the manufacturer’s instruction. The MIC was defined as the lowest 
antibiotic concentration with less bacterial growth compared with the 1:100 diluted controls 
(for pyrazinamide 1:10 diluted controls).  
4.3.4 Microtitre Sensititre™ plates – Study III & IV 
The microtitre plates were used containing lyophilized freeze-dried antibiotics at increasing 
concentrations, enabling the simultaneous determination of 14 antibiotics. Standardised 
bacterial inoculums were added to the wells, incubated at 37ºC and read after 10-21 days, 
assisted by an inverted mirror. The H37Rv strain was included as an internal control in all 
plates. The MIC was defined as the lowest concentration able to inhibit visible growth. The 
sensitivity of detecting resistance of drugs compared to BACTEC MGIT 960 is still variable, 
over 95% for rifampicin but 72% for ethambutol (MYCOTB plate) (68).  
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4.4 WHOLE GENOME SEQUENCING (WGS) 
WGS provides a comprehensive analysis of the genome (132) and was used in Study III for 
relapse confirmation. . DNA is extracted from an M.tuberculosis isolate, sequenced and the 
result of the sequencing is compared with a reference sequence in order to detect single 
nucleotide polymorphisms (SNPs), i.e. variations in a single nucleotide, insertions or 
deletions (133). A true relapse was defined as less genetic distance than 6 SNPs difference 
between the paired isolates (134). WGS requires pure, double-stranded DNA to perform well 
and cannot be used on direct sputum samples, as currently. 
 
 
 
 
 
4.5 DRUG CONCENTRATION MEASUREMENTS 
Liquid-chromatography mass-spectrometry (LC-MS) was used to determine the total plasma 
drug concentrations in Study IV. The free fraction of the drug was calculated using 
previously published values of protein binding in humans. In LC, liquid solvents are passed 
through a column containing a solid adsorbent, with strong affinity for hydrophobic 
molecules, and thereby the compounds are separated depending on their degree of interaction 
with the adsorbent material. The chromatographically separated compounds are then detected 
by mass spectrometry. Mass spectrometry measures the mass-to-charge ratio of charged 
particles that are separated by electromagnetic fields and can quantify the amount of a 
compound in a sample (135). Internal standards are vital to account for day-to-day variability 
of the method. 
4.6 EPIDEMIOLOGY 
4.6.1 Cohort study design  
Cohort study design was used to enable investigation of the association between exposure 
and outcome and to follow participants over time, up to the outcome of interest or censoring 
(death, lost to follow up etc) (Study III & IV). Multiple outcomes can be studied and time to 
event data is created, allowing for survival analysis, suitable for relatively common outcomes 
(136). 
4.6.2 Random error 
Random error is unpredictable variation by chance and can be reduced by an increase in the 
number of observations. The confidence interval (CI) is a range in between two values and 
the level of confidence (p-value) tells us the probability that the true value lies within this 
range. At a significance level of <0.05, as in our studies, the CI would likely include the true 
value in 95 out of 100 repeated studies (137).   
Principle steps of WGS 
1. Culture of M.tb isolate (LJ/MGIT) 
2. DNA extraction 
3. Whole genome sequencing 
4. Analysis of sequence date 
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4.6.3 Bias 
Apart from random error, different forms of bias (potentially leading to incorrect conclusions) 
are divided into three main categories; selection bias, information bias and confounding.  
Selection bias occurs from systematic differences in characteristics between the study 
participants and the population from which they are selected; for instance, oversampling 
healthier patients able to come for study enrolment (137). In clinical studies screening logs 
are kept to assess the risk of selection bias. Selection bias was minimized in Study III since 
97% (158/163) of all patients were included in the analysis.  
Information bias refers to the correctness of the data, i.e. errors in the classification of 
exposure and outcome. Prospectively collected data avoids the misclassification of exposures 
depending on the outcome. Missing data might be a form of information bias, if the 
missingness is differential. Non-differential missing data, i.e. missing by chance, might only 
dilute the result.  
Confounding bias is a variable linked both with the exposure and the outcome and unevenly 
distributed between the two comparison groups, resulting in a distortion of the association. 
An example is a study of hospitalised patients showing a protective effect of obesity and risk 
of death, when this might be explained by the presence of a serious medical illness, resulting 
in both low BMI and high risk of death. Residual confounding can be reduced, but perhaps 
not eliminated, in the analysis stage by statistical adjustment for possible confounders (136).  
4.7 STATISTICAL CONSIDERATIONS 
In general, a p-value <0.05 was considered significant for all studies and all tests were two-
sided. Normal distribution of continuous variables was assessed using histograms. For 
comparison of categorical data, Pearsons’ chi-square test or Fisher’s exact test (for small 
sample sizes) were used.  
The time to event data in Study III was analysed using Cox proportional hazard regression 
models. Cox regression estimates the risk of experiencing an outcome, a so called hazard 
function, comparable to a speed. Unlike Poisson regression, the individual hazard rate cannot 
be estimated, only the hazard rate ratio between two different groups, concurrently adjusted 
for the effect of other variables, often confounders in a multivariable regression model. The 
proportional hazard assumption for Cox models always has to be tested, since the underlining 
assumption is that the hazard rates are proportional over time, which can be tested using 
Schoenfeld residuals, for example. Cox proportional hazard models automatically adjust for 
the time scale, in this case since start of MDR-TB treatment and no assumptions regarding 
the distribution are needed (138). The Cox regression model was chosen in Study III for the 
unique availability of time to event data and the view that the time to poor outcome is of 
interest, not just the final outcome. In a country with a high proportion of successful 
treatment outcome, the time to event is of interest to discern differences between groups of 
patients.  The non-parametric Kaplan-Meier estimator visualises the probability of staying 
outcome free over time and was used to visualize differences in time to sputum culture 
conversion in Study III. The Kaplan-Meier estimator can be used for censored data, with the 
assumption that censoring is non-informative censoring (138).  
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4.8 ETHICAL CONSIDERATIONS 
Medical ethics relies on the principles of non-maleficence, justice, beneficence and autonomy 
(139).  The axiom “Primum non nocere”, implores the medical profession to, above all, not 
do our patients harm (non-maleficience). Health care should be fair and equal (justice). In 
medical research the well-being of the patient or the study participant should be the primary 
goal (beneficience), through the means of a thorough cost-benefit analysis regarding potential 
risks. Patient autonomy, which emphasises the right of the patient to make independent 
decisions, is a term closely linked to informed consent. 
Studies I & II. Both studies involved growth and enrichment of MDR/XDR-M.tuberculosis 
isolates, exposing the staff to an increased bio-hazard. However, the laboratory work was 
performed at the TB laboratory at Karolinska University Hospital by experienced staff, 
minimising this risk. No ethical approval was needed. 
Study III. A strength of this retrospective cohort study is the completeness of the data, with 
all MDR-TB patients in Sweden consecutively included over a 22-year period. This was 
enabled through a wavering of an informed consent, a potential breach of patients’ integrity.  
The need of patient approval would have likely resulted in a marked decrease in patient 
inclusion, especially since many patients had returned to their country of origin and some had 
died.  Efforts were made to minimise this breach of integrity by the use of only three medical 
staff bound by confidentiality in performing data collection. The knowledge gained from the 
study is deemed to exceed the potential harm to the study participants. Approved by the 
Regional Ethic Board of Linköping (Dnr: 2012/197-31).        
Study IV. Repeated blood samples were the main cause of patient discomfort in the study. 
Three blood samples were collected after two weeks of treatment, when most patients were 
out-patients. More blood samples would have made PK estimates more accurate, but in the 
interest of patient comfort and time, a minimal number of samples were chosen.   
The use of an informed consent in order to respect patients’ autonomy should ensure that the 
patient makes an independent, non-coerced, knowledgeable decision. The patient might feel 
obliged to participate in order to please the doctor, which is why specially trained study 
nurses informed and included the patients. Patients were also informed, orally and in writing, 
that they were free to leave the study, without providing any reason, with no effect on their 
future treatment. The study was performed according to Good Clinical Practice and the 
Helsinki Declaration.  
Finally, one can argue from a deontological, or duty-based perspective, that the harm from 
blood sampling goes against our duty as doctors of non-maleficence. From a utilitarian 
perspective, on the other hand, the benefit to society is also taken into account, i.e. the 
potential usefulness of the study for other patients (139). The Swedish study has revealed 
unexpectedly low drug exposure during standard treatment, important knowledge for 
clinicians treating TB. In conclusion, the anticipated benefits of the studies are considered to 
outweigh the risks. Approved by the Regional Ethic Board of Linköping (Dnr: 2012/197-31).     
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5 RESULTS   
5.1 STUDY I 
Trimethoprim-sulfamethoxazole has in vitro activity against highly resistant M.tuberculosis 
isolates, at clinically achievable doses.  
The 84 drug-resistant strains tested for TMP-SMX in 7H10 solid medium showed an MIC 
distribution ranging from 2.4 to 38 mg/l of SMX (0.125/2.4 to 2/38 mg/l of TMP-SMX) 
(Figure 9). 
 
Figure 9. Effects of trimethoprim-sulfamethoxazole (TMP-SMX) on M. tuberculosis. 
MIC distribution of TMP-SMX for the M. tuberculosis isolates (n=84) tested using 
Middlebrook7H10 medium, shown by bars shaded as follows: non-MDR/XDR-TB (grey), 
XDR-TB (black), and MDR-TB (hatched). 
In another experiment using liquid 7H9 medium, TMP showed no effect on its own, or in 
combination with TMP-SMX, which is why the results of the active component SMX are 
reported. The extracellular effect of SMX was 19 mg/L.  
The intracellular growth was evaluated using a macrophage model where H37Rv-lux was 
phagocytized by macrophages and emitted luminescence was measured. The intracellular 
MIC90 of SMX was 76 mg/L. Even at higher levels of SMX (120 mg/L) some viable bacilli 
were seen, indicating low intracellular penetration of the drug. The extra-and intracellular 
effect was evaluated in triplicates with an experimental method using 96-well plates 
(Sarstedt) with Middlebrook 7H9 broth. 
  
MIC (mg/L) of TMP-SMX 
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We also performed an exploratory analysis of potential targets for the fAUC0–24/MIC ratio 
(25, 50, and 75) for SMX. The probability of target attainment and cumulative fraction 
response values for different doses up to 7,200 mg of SMX was estimated using Monte Carlo 
simulations (105). A cumulative fraction response of 90%, including MDR- and XDR-
M.tuberculosis isolates, was reached at doses of 2,400 mg, 3,600 mg, and 7,200 mg of SMX 
using target indices of 25, 50, and 75, respectively (Figure 10). If a PK/PD target of 25 is 
used, as suggested for melioidosis and for M.tuberculosis (140, 141), one tablet of Bactrim® 
forte (co-trimoxazole) thrice daily (2400 mg daily) is sufficient to kill over 90% of the 
MDR/XDR-TB isolates. 
 
 
 
 
Figure 10. Probability of target attainment (PTA) after selected different daily 
sulfamethoxazole doses and a fAUC0-24h/MIC ratios of 25. 
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5.2 STUDY II 
Meropenem-clavulanate acid is effective against MDR/XDR-TB isolates in vitro 
We investigated the activity of MEM-CLA against 68 M. tuberculosis isolates. We included 
predominantly MDR/XDR-TB isolates. Using Middlebrook 7H10 medium, all but four 
isolates showed an MIC distribution of 0.125 to 2 mg/L for MEM-CLA, below the non-
species-related breakpoint for MEM of 2 mg/L deﬁned by EUCAST, and pertaining to a 1g 
thrice daily dosing regimen.  
The range of the MIC distribution was 0.125-2 mg/L for MEM in combination with CLA 
(Figure 11). Most of the MICs were normally distributed following a wild-type pattern below 
the non-species-related breakpoint for MEM of 2 mg/L. However, four isolates had high 
MICs (16 and 32 mg/L respectively) and were deemed resistant. The resistant isolates also 
showed extensive resistance to other structurally unrelated anti-TB drugs, suggestive of poor 
drug permeability as a possible resistance mechanism. The MIC of the control strain H37Rv 
was 1 mg/L. 
 
 
 
Figure 11. The MIC distribution of meropenem-clavulanic acid for the M. tuberculosis 
isolates (n=68) tested using Middlebrook 7H10 medium, shown by bars shaded as follows: 
non-MDR/XDR-TB (grey); XDR-TB (black), and MDR-TB (hatched). The MIC distribution 
shows the concentration of meropenem, as the concentration of clavulanic acid was fixed 
uniformly at 64 mg/L. 
  
  36 
5.3 STUDY III 
Minimum inhibitory concentrations of fluoroquinolones and pyrazinamide susceptibility 
correlate to clinical improvement in MDR-TB patients 
There were 163 patients diagnosed with MDR-TB in Sweden from 1992-2014, with a marked 
increase in the incidence of MDR-TB during this time period, as shown in Figure 12. The 
median age was 29 (range 1-85 years) and 42.4% were female (67/158). The vast majority of 
patients were born outside of Sweden (94.3%; 149/158). Comorbidities were infrequent, the 
most common being HIV (10 patients) and diabetes mellitus type 2 (seven patients). PTB was 
the most common form of TB (122; 77.2%), of which the majority were sputum smear 
positive (65/118, 55.1%). 
Figure 12. The trend in TB and MDR-TB in Sweden. 
 
Resistance to important first-and second line drugs was 52.5% for pyrazinamide, 43.7% for 
ethambutol, 15.2% for any second-line injectable drug (amikacin, kanamycin or 
capreomycin) and 10.1% for ofloxacin. Patients previously treated for TB (first/second-line 
treatment) were more likely to harbour an M.tuberculosis isolate resistant to fluoroquinolones 
(22.2% vs 5.5% for untreated patients; p=0.002) and second-line injectables (24.4% vs 11.8% 
respectively; p=0.049), but not resistant to ethambutol or pyrazinamide.  
The most common backbone treatment was ethambutol, pyrazinamide, levofloxacin and 
amikacin, in combination with either prothionamide, cycloserine or linezolid, in order of 
decreasing frequency. There were 48 (30.3%) patients eligible for the WHO MDR-TB short 
course regiment, although it was not in use or recommended during the study period.   
MIC determination was possible for 142 of 158 M.tuberculosis isolates (10 isolates not 
stored, 6 with no growth). An increase in MICs of levofloxacin, ofloxacin and ethionamide 
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was significantly associated with an increased risk of poor treatment outcome (composite 
outcome of death/failure/relapse and death/failure/relapse/lost to follow-up) (Table 8). In a 
complete case analysis, the result was still significant after adjustment for confounders such 
as age, gender and year of diagnosis. However, for patients treated with a fluoroquinolone 
and with a susceptible isolate, there was no significant association for levofloxacin in the 
multivariate model (aHR 1.70 95% CI 0.85-3.40 p=0.134) although the association remained 
significant for ofloxacin (death/failure/relapse/lost to follow-up, aHR 1.25 95% CI 1.02-1.53 
p=0.030) 
Other variables associated with treatment outcome were diabetes and age of diagnosis, with a 
4.5 times increased rate of death/failure/relapse/lost to follow-up for patients older than 40 
years (aHR 4.51 95% CI 1.74-11.67 p=0.002).  
Table 8. Univariate analysis regarding MICs of first- and second line TB drugs and 
composite treatment outcome (death/failure/relapse and death/failure/relapse/lost to 
follow-up). The analysis was restricted to patients with a susceptible isolate who received treatment 
with the drug or group of drugs analysed. For example, for analysis of levofloxacin, all patients treated 
with a fluoroquinolone with a levofloxacin/ofloxacin susceptible isolate were included. 
   Death/Failure/Relapse 
nr= 15/158 
 
 Death/Failure/Relapse/Lost to 
follow-up  
nr=22/158 
 
MIC mg/L 
 
Total 
 
 
 
 
HR (95% CI) 
 
p-value 
  
HR (95% CI) 
 
p-value 
 
Group A         
Levofloxacin  125  2.08 (1.10-3.92) 0.024  2.00  (1.19-3.37) 0.009  
Moxifloxacin  125  2.09  (0.30-14.52) 0.458  2.06  (0.42-10.07) 0.374  
Ofloxacin  125  1.33  (1.03-1.73) 0.030  1.43  (1.19-1.72) <0.001  
Group B         
Amikacin  118  0.98 (0.77-1.24) 0.852  0.98  (0.80-1.18) 0.799  
Kanamycin  118  1.01 (0.92-1.10) 0.899  1.03  (0.98-1.09) 0.265  
Capreomycin 115  1.06  (0.94-1.19) 0.326  1.08  (1.01-1.16) 0.025  
Group C         
Prothionamide 77  1.11 (0.79-1.56) 0.555  1.17 (0.92-1.49) 0.205  
Ethionamide  77  1.25  (1.05-1.48) 0.013  1.17  (1.01-1.37) 0.038  
Cycloserine  85  0.95 (0.82-1.11) 0.522  0.96  (0.86-1.07) 0.459  
Linezolid  62   0.89 (0.00- 2141.01) 0.977  5.79  (0.02-1716.30) 0.545  
Group D         
Ethambutol  74  0.88  (0.65-1.21) 0.436  0.84  (0.62-1.16) 0.289  
PAS  38  0.06  (0.00-55.57) 0.426  1.11  (1.03-1.19) 0.009  
         
Clinical data         
Gender 154  1.08 (0.34-3.42) 0.893  1.33  (0.52-3.39)   0.548  
Age 154  1.07 (1.04-1.10) <0.001  1.05  (1.03-1.08) <0.001  
Year of 
diagnosis 
154  0.93 (0.86-1.02) 0.109  0.96  (0.89-1.03) 0.248  
Diabetes 152  8.97 (1.87-43.1) 0.006  8.09  (2.30-28.5) <0.001  
For all drugs above, the analysis was restricted to patients with a susceptible isolate who received treatment 
with the drug or group of drugs analysed. For example, for analysis of levofloxacin, all patients treated with a 
fluoroquinolone with an ofloxacin susceptible isolate were included. No patients were treated with bedaquiline 
or delamanid an no MIC determination of pyrazinamide was performed. Analysis of MIC of clofazimine not 
possible due to too few treated patients. PAS= para-aminosalicylic acid. Diabetes mellitus type II, no cases of 
type I Non-significant variables: gender, alcohol, smoking, previous TB treatment, HIV, Body Mass Index (BMI), 
cavitary pulmonary TB, pre-XDR/XDR-TB, number of resistant drugs.   
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There were 122 PTB patients and sputum culture conversion was achieved for 84 of the 87 
patients with available information of time to sputum culture conversion. The median time to 
conversion was 46 days (IQR 13.8-79.3). After adjustment for potential confounders such as 
gender, age, year of diagnosis, previous TB and smear positivity, variables such as previous 
TB treatment, smear positivity at diagnosis and pyrazinamide resistance were significantly 
associated with an increased time to sputum culture conversion.  
On the other hand, pyrazinamide treatment was not significantly associated with time to 
culture conversion after adjustment of confounders in a complete case analysis. Almost a 
third of patients (31.7%, 26/83) received treatment with pyrazinamide despite pyrazinamide 
resistance, in most cases due to a delay in the DST results. Thus, when stratifying on 
pyrazinamide treatment and resistance, PZA treatment for patients with PZA susceptible Mtb 
isolates was significantly associated with a reduced tSCC of one month (aHR 2.25 95% CI 
1.27-3.99 p=0.005).  
However, there was no discernible effect on sputum culture conversion for patients receiving 
pyrazinamide treatment with a resistant isolate. The difference in time to sputum culture 
conversion depending on pyrazinamide treatment is visualised in a Kaplan-Meier curve 
Figure 13. 
 
Figure 13. Kaplan-Meier failure-curve for time to sputum culture conversion from start 
of MDR-TB treatment and treatment of pyrazinamide (tx_pyrazinamide=1, red line). 
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5.4 STUDY IV 
Low drug concentrations of first-line drugs are commonly low in TB-patients 
There were 31 consenting adult TB-patients included in the study. The median age was 33 
years (IQR: 26-44) and the majority of patients were female and originated from sub-Saharan 
Africa (61%, 19/31). Comorbidities according to the Charlson comorbidity index (142) were 
infrequent (3/31, 10%) and there were no HIV co-infected patients. Twenty-six patients had 
bacteriologically confirmed TB and among pulmonary TB patients, 21% (5/24) had cavitary 
disease and 25% (6/24) were sputum smear positive. All patients were initially deemed cured 
at the time of treatment completion, but two patients experienced recurrence of TB.  
After two weeks of treatment, lower than recommended drug concentrations were detected in 
42 % of the patients for rifampicin (<8 mg/L), 19 % for isoniazid (<3 mg/l), 16% for 
ethambutol (<2 mg/L) and 27% for pyrazinamide (<35 mg/L). The median Chigh for 
rifampicin was 10.0 mg/L (range 0.5-23.0 mg/L), for isoniazid 5.3 mg/L (range 1.6-9.8 
mg/L), for ethambutol 3.3 mg/L (range 0.6-5.4) and for pyrazinamide 41.1 mg/L (range 23.1-
63.0) for pyrazinamide. The distribution of plasma levels of Chigh for each of the four first-
line drugs is displayed in Figure 14.  
 
Figure 14. Distribution of plasma levels of Chigh for first-line TB drugs at week 2 in 
patients with active TB. 
 
Footnote: Individual total drug levels of rifampicin, isoniazid, ethambutol and pyrazinamide are plotted 
against the left y-axis whereas the right y-axis corresponds to the pyrazinamide plasma level. For 
each individual patient the same dot style is used throughout for all drugs. Horizontal bold lines 
represent median levels and horizontal dotted lines show the lower recommended limit for each drug 
according to the literature (RIF 8 mg/L, INH 3 mg/L, PZA 35 mg/L and EMB 2 mg/L) (119) (110). 
RIF=rifampicin INH=isoniazid EMB=ethambutol PZA=pyrazinamide. 
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Individual rifampicin concentrations displayed significantly more fluctuation over time 
compared to isoniazid concentrations (p<0.001). The median Chigh of isoniazid was markedly 
lower for fast acetylators compared with slow acetylators (3.2 vs 6.2 mg/L, 0=0.002), at all 
measured time points (weeks 2, 4 and 12).  
In MGIT, the median MIC levels for susceptible isolates were 0.064 mg/L (range 0.016-
0.125) for rifampicin, 0.032 mg/L (0.032-0.064) for isoniazid, 1 mg (1-4 mg/L) for 
ethambutol and 32 mg/L (16-100 mg/L) for pyrazinamide. None of the isolates exhibited any 
known drug resistance mutations by the WGS-analysis for the first-line drugs.  
When comparing the drug exposure with the individual MICs, median Chigh/MIC for 
rifampicin, isoniazid, ethambutol and pyrazinamide were 164, 128, 2.5 and 1.3 respectively 
whereas median AUC0-6h/MIC was 636 (range 156-2759) for rifampicin and 351 (range 72-
895) for isoniazid. The corresponding calculated ƒChigh/MIC and fAUC0-6h/MIC for 
rifampicin were 33 (range 3-157) and 128 (range 31-554) respectively.  
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6 DISCUSSION   
6.1 MAJOR FINDINGS 
We found high in vitro effect of TMP-SMX and MEM-CLA, even against M.tuberculosis 
isolates with resistance to multiple other TB-drugs (MDR/XDR-TB) (Study I&II). In our 
retrospective cohort study, the overall treatment outcome in MDR-TB patients in Sweden 
1992-2014 (no=158) was favourable with 86% successful treatment outcome and seven 
deaths. Variables associated with unsuccessful treatment outcome (death/failure/relapse) were 
increments of MIC of fluoroquinolones as well as age and diabetes. The appropriate use of 
pyrazinamide in the treatment for MDR-TB was associated with an approximate reduction in 
time to sputum culture conversion of a month (Study III). Finally, drug concentrations were 
commonly lower than recommended for susceptible TB patients, despite standard treatment 
dosages (Study IV).  
6.2 GENERAL DISCUSSION 
Clinicians pose themselves many questions regarding how to best treat their patients – what is 
the best choice of drugs, ideal dose and optimal treatment duration for this particular 
individual? In TB-patients, we want to ensure a rapid halt of contagiousness, tolerable 
treatment regimens and a durable cure, without acquired drug resistance. In order to do this, 
we need to consider the intricate relationship between host (pharmacogenetics, immune 
status), pathogen (bacterial resistance and virulence) and drug exposure (PK characteristics).  
6.2.1 The quest for new drug regimens – in with the new, in with the old  
The repurposing of drugs by finding new applications for already approved drugs can reduce 
time to approval of new drug alternatives. We studied the in vitro effect on MDR-
M.tuberculosis isolates of the readily available TMP-SMX (Bactrim®/co-trimoxazole) 
(Study I). Our tentative breakpoint of 2/38 mg TMP-SMX has been endorsed by others (143, 
144). The results have also recently been corroborated in a study of 153 MDR-M.tuberculosis 
isolates where the MIC distribution was <0.05/1 – 1.7/32 mg/L of TMP-SMX, although 
performed using a colorimetric method (resazurin microdilution in 7H9). No sign of 
resistance was seen for patients previously treated with TMP-SMX (n=51) (144). Moreover, 
in a small PK study where patients received 480 mg of SMX daily, only one out of eight 
patients had a ƒAUC0-24h/MIC ratio of SMX greater than 25, a previously suggested PK/PD 
target (145). Our exploration of potential targets for fAUC 0-24 h/MIC with Monte Carlo 
Simulations showed that an adequate cumulative fraction response (CFR > 90%) was 
achieved at doses of 2400 mg of SMX daily, corresponding to a clinically tolerable dose of 
three tablets of Bactrim® forte daily. It should be emphasized that the PK/PD target of 25 is 
an expert opinion extrapolated from PK/PD targets for melioidosis (caused by the gram-
negative bacteria Burkholderia pseudomallei), but not validated clinically for TB. 
There is limited clinical data regarding TMP-SMX as large studies, as well as PK/PD dose-
ranging studies, are lacking. The active component of the combination, SMX, has poor lipid 
solubility and exhibits poor intra-cellular activity, limiting its use to complicated MDR-TB 
cases during the early phase of disease, where bacteria are found extracellularly (146).  
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Another repurposed drug, MEM-CLA, is recommended as a Group C drug against MDR-TB 
(77). Carbapenems are intrinsically a poor substrate for the beta-lactamase of M.tuberculosis 
(89) and a synergistic effect with clavulanic acid has been shown (147). Study II is in line 
with previously reported results where MEM-CLA displayed high bactericidal activity even 
against drug-resistant M.tuberculosis isolates, with MICs predominantly below 2 mg/L (89).  
A small clinical randomised controlled trial (RCT) (no=30) showed a significant reduction in 
bacterial load (1.5 decline of log CFU count) when MEM-CLA (2 g MEM and 500/125 mg 
of amoxicillin-clavulanic acid thrice daily) was added to standard treatment of susceptible TB 
for two weeks (148). There is however limited clinical data and the short half-life of one hour 
requires frequent intravenous dosing, limiting its use. Ertapenem is a newer carbapenem with 
a longer half-life, allowing for once daily administration. Five cases of pre-XDR/XDR-TB 
patients treated with ertapenem in combination with WHO recommended MDR-TB 
treatment, resulted in a successful outcome for four patients (149). In a retrospective study 
including 180 patients, Tiberi and co-authors suggested that MEM-CLA acid is more 
effective than imipenem-clavulanic acid in the treatment of MDR/XDR-TB. However, it 
should be noted that there were significantly more patients with fluoroquinolone-resistance in 
the imipenem group (79% vs 48.9%, no. 84) and since no multivariable analysis was 
performed (150) there is a risk of confounding.  
Since the in vitro activity of meropenem without a beta-lactamase inhibitor is relatively poor 
(MIC levels up to 32 mg/L) (151), meropenem is only recommended when given together 
with amoxicillin-clavulanic acid (77). New beta-lactamase inhibitors include avibactam and 
vaborbactam, and have been combined with beta-lactam antibiotics (i.e. zavicefta®; 
ceftazidim-avibactam and vabomere®; meropenem-vaborbactam) (152, 153). The drawback 
of only intravenous availability has been overcome by tebipenem, the first orally available 
carbapenem, approved in Japan for treating children with drug-resistant pneumococci. 
Tebipenem inhibits the beta-lactamase of M.tuberculosis and might be worth exploring 
further, clinically (154). Carbapenems are a treatment option in very difficult to treat patients 
and are generally well tolerated (155), although the long-term effect of a changed microbiota 
has not been evaluated for TB patients.  
The drug bedaquiline, introduced clinically in 2013, has very recently been given the highest 
recommendation for MDR-TB treatment and its use is increasing world-wide. The drastically 
changed recommendations include an upgrading of linezolid and cycloserine, at the expense 
of second-line injectables.  
Not only are the recommended treatment regimens changing, the way we view resistance and 
DST is currently under scrutiny. 
6.2.2 Reliable drug susceptibility and MIC-testing do matter 
DST of M.tuberculosis should be performed but it needs to be reliable and reproducible to 
ensure appropriate treatment choices. Access to DST will also avoid patients experiencing 
adverse events due to ineffective drugs. Increased mortality has been seen for patients with 
discordant DST results (156). In a multi-centre study from TB high-burden countries, 634 TB 
patients were included, of which 193 patients (30.4%) had MDR/XDR-TB. Comparing DST 
results from a local laboratory with the reference laboratory, there were 121 discordant results 
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and consequently 27 patients (22.3%) were assessed as having received inadequate treatment 
regimens according to WHO guidelines, compared to only eight (1.8%) patients with 
concordant DST results. Similarly, there were also marked differences in mortality between 
the two groups (17% mortality with concordant DST versus 30.8% with discordant DST 
p=0.030) (156). 
In Study III, the decreased time to sputum culture conversion was only seen among patients 
treated with pyrazinamide and diagnosed with a pyrazinamide-susceptible M.tuberculosis 
isolate, whereas no reduction was seen in patients treated with pyrazinamide with a 
pyrazinamide-resistant M.tuberculosis isolate. In the largest meta-analysis of MDR-TB so far, 
the use of pyrazinamide was also associated with slightly lower mortality (adjusted risk 
difference 0.03), but only if the isolates were susceptible for pyrazinamide (78). These 
findings highlight the need of a reliable DST for pyrazinamide to identify individuals who 
may benefit from pyrazinamide treatment. Unfortunately, pyrazinamide DST is rarely 
performed in many high-burden settings. Unavailable or inaccurate DST results might lead to 
standardised or inaccurate treatments, stressing the need for a reliable DST for all second-line 
drugs.  
6.2.2.1 Resistance is continuous, not binary 
For the DST to be of clinical value, the critical concentration has to be relevant and validated, 
which unfortunately is often not the case. In Study III, there was no correlation between 
treatment outcome and DST results with current critical concentrations. Admittedly, critical 
concentrations were difficult to evaluate in a small study like ours, especially given that 
several drugs were given. In the aforementioned large individual patient data meta-analysis 
by Ahmad and co-authors, drug resistance was associated with worse treatment outcome (78). 
However, our study exemplifies the difficulty in setting relevant critical concentrations and 
highlighting the continuous nature of resistance. Increments of MIC for levofloxacin and 
ofloxacin were, however, associated with unsuccessful treatment outcome, including relapse. 
Previous studies have shown higher MICs of isoniazid and rifampicin, although still below 
the critical concentrations, to be predictive of poor treatment outcome (157). Similarly, a 
recent study showed an association between higher baseline MIC for either rifampicin or 
isoniazid and an increased risk of relapse, even if all M.tuberculosis isolates were susceptible 
according to current critical concentrations (158). In this case-control study, M.tuberculosis 
isolates from 54 relapse TB patients were included from a previously performed study and 63 
cured TB patients were randomly selected from the same cohort. In a predictive model based 
on MICs and clinical characteristics, the MIC level of rifampicin or isoniazid, lack of sputum 
culture conversion after two months of TB-treatment as well as being underweight showed 
independent association with increased risk of relapse. The authors of this study concluded 
that the level of resistance of the M.tuberculosis isolate is at least as important as clinical 
characteristics such as underweight and cavitary TB, previously identified as a risk factor for 
TB relapse (158). As previously stated, relapse of TB is thought to be caused by the inability 
to clear persisting bacteria which often hide in a necrotising caseum where drug penetrations 
may vary (159). It is possible that it is the combination of a sub-population of M.tuberculosis 
together with an increased MIC residing in difficult to treat locations that makes eradication 
more difficult.  An MIC-based approach to select patients for shorter treatment durations with 
less risk of relapse has therefore been suggested (158).  
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Since binary breakpoints are difficult to define and have the inherent risk of oversimplifying 
resistance, the testing of two breakpoints has been suggested, similar to that of isoniazid (0.1 
and 0.4 mg/L) (160). An intermediate-susceptible dose-dependent category for TB has been 
proposed, similar to other bacteria, where resistance can be overcome by increased dosage 
(160) but this is not widely accepted. For example, intermediate categories, or even more 
appropriate “susceptible, increased exposure” as defined by EUCAST, have been suggested 
for isoniazid, pyrazinamide and rifampicin (161, 162). A clinical breakpoint in MGIT of 
moxifloxacin of 1.0 mg/L, compared to a critical concentration of 0.25 mg/L, when increased 
dosage of 800 mg daily is used, has recently been recommended by WHO (40).  
Figure 15. M.tuberculosis isolates with increased resistance compared to ECOFF and/or the 
critical concentration that might still be treated with increased dosing, belonging to an 
intermediate category, or “susceptible, increased exposure” (I).  
 
6.2.2.2 MIC values – advantages as well as pitfalls 
In contrast to DST results, MIC determination allows for a more nuanced understanding of 
the level of resistance. MIC determinations in MGIT are costly, time-consuming and labour-
intense. Microtitre plates allow for the simultaneous MIC determination of 14 different drugs, 
at a low cost with results within two weeks, making MIC determinations more accessible in 
clinical practice (67). However, MIC methods, similar to other methods, are prone to some 
variability. A reported MIC value should not be viewed as the “true” value, but as providing 
information whether the isolate is of wild-type or not (66). In other words, an MIC value 
should be viewed as predictive of probability of cure on a continuous scale rather than an 
exact value. 
With these caveats in mind, MIC values might still guide clinicians regarding the degree of 
resistance to a drug, in order to deduce what drug exposure might be needed. Knowledge of 
the drug exposure in our patients is also needed. TDM is a useful tool to elucidate the 
relationship between bacterial resistance and individual drug exposure. 
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6.2.3 Therapeutic drug monitoring – a torch in the dark 
6.2.3.1 Low drug exposure common in TB-treatment 
Low drug concentrations are common in TB-treatment, even in a high-resource setting with 
high quality drugs, using recommended dosing in an otherwise healthy cohort (Study IV). In 
a meta-analysis, the frequency of low drug concentrations at 2 hours (C2h) for first line drugs 
was shown to be 67% for rifampicin, 43% for isoniazid, 27% for pyrazinamide and 12% for 
ethambutol. Subtherapeutic levels of rifampicin and isoniazid were more frequently seen in 
the meta-analysis than in Study IV (rifampicin 67% vs 42%, isoniazid 42% vs 19%), 
possibly since the meta-analysis mainly included studies from high-burden countries and not 
all studies with strict fasting conditions as ours (163). However, AUC calculation is a more 
precise measure of drug exposure, since C2h might be low due to delayed absorption rather 
than low drug exposure. The median AUC0-6 of rifampicin in Study IV was 35, marginally 
lower than the mean AUC at steady state of 38.73 mg·h/L from a recent meta-analysis, 
displaying the representativeness of the data (164).  
Interestingly, patients in Study IV with low rifampicin concentrations (<8 mg/L) had 
significantly higher TBscore II, possibly explained by altered PK characteristics in severely 
ill patients. Indeed, reduced absorption of rifampicin has been seen in critically ill patients 
(165) whereas the volume of distribution of lipophilic drugs such as rifampicin is not as 
affected (27). An additional contributing factor is that observed reduced drug concentrations 
after a few weeks of rifampicin treatment are not only due to autoinduction of metabolizing 
hepatic enzymes, but also decreased oral bioavailability (93% to 68% after three weeks’ 
treatment) due to the induction of pre-hepatic metabolism (166). 
The median Chigh in Study IV of pyrazinamide was 41.1 mg/L, lower than the identified cut-
off by Pasipanodya where a Cmax below 58.3 mg/L was associated with poor two-month 
sputum culture conversion (121). In Study IV, all but one patient had sputum culture 
converted by month 2, despite the majority having lower Chigh than 42 mg/L. Our study did 
not have sufficient power to assess differences in microbiological response.  
When comparing the drug exposure in our cohort with the individual MICs, the PK/PD ratio 
was adequate, even for patients with very low drug concentrations, due to the low MIC range 
in the study (rifampicin range 0.016-0.125 mg/L). The median AUC/MIC of rifampicin was 
636, significantly higher than the suggested target value of 271 (167). It should be noted that 
the tentative PK/PD target for rifampicin was derived from a murine aerosol infection model 
with dose fractioning over six days and has not been validated in human beings. Two 
previous studies with Monte Carlo simulations have reported low probabilities of target 
attainment of rifampicin AUC/MIC ≥ 271 at 600 mg daily (168, 169), illustrating that 
adjustment of the target might be needed. However, PK/PD targets derived from murine 
models use monotherapy and does not take the synergistic effect of drug into account (169). 
The fact that none of the patients had a severely impaired immune system or HIV, might also 
have contributed to the favourable outcome, although the only two patients with relapse had 
low levels of rifampicin during the treatment course. Studies show that rifampicin appears to 
accumulate intracellularly with an alveolar macrophage drug concentration versus a plasma 
drug concentration of around 16:1 (170), but it is unknown whether this ratio is static and if 
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plasma concentrations always reflect intracellular drug concentrations. It should be pointed 
out that Study IV was not sufficiently powered to study differences in mortality or final 
treatment outcome between patients with low or adequate drug exposure.  
6.2.3.2 Does low drug exposure matter?  
As shown in Table 6 in the Introduction section herein, there is conflicting evidence whether 
subtherapeutic drug concentrations are linked with poor clinical outcome, with 11 out of 23 
studies showing an association. In a Danish study in a similar setting to ours, treatment failure 
(five out of 32 patients) was more common in patients with lower than normal C2h drug 
concentrations of isoniazid and/or rifampicin (118). In a South African study, the three most 
important predictors of a poor clinical outcome were identified as pyrazinamide AUC0-24h 
≤363 mg·h/L, rifampicin AUC0-24h ≤13 mg·h/L and isoniazid AUC0-24h≤ 52 mg·h/L (121). In 
a meta-analysis up to 2014, only three out of 12 studies assessing outcome (culture 
conversion or treatment outcome), showed an association between subtherapeutic levels and 
unsuccessful treatment outcome (163). Possible reasons for the conflicting results from the 
studies are differences in outcome definitions, study populations, PK sampling, drug 
formulations, HIV co-morbidity as well as too low power and too subtle variations in drug 
exposure, to have a clinical impact (110).  
Fast acetylators of isoniazid (homogenous for the wild-type gene N-acetyltransferase 2 
(NAT2) had significantly lower drug exposure at all measured time points in our study 
(Study IV). Acetylator status of isoniazid varies across populations, where slow-acetylator 
status is related to an agriculture/postural life-style and more common in Scandinavia, as 
compared to in Japan where 53.5% of patients in a pharmacogenetic RCT of isoniazid were 
of the fast-acetylator genotype (171). In the aforementioned RCT, the dose of isoniazid was 
adjusted according to NAT2 genotype, rather than plasma concentrations, and reduced 
toxicity as well as improved clinical progress were seen (171), illustrating the possibility of 
pharmacogenetic-based therapy.  
6.2.3.3 Drug exposure in MDR-TB patients – a lesser studied field 
Less is known of drug exposure in MDR-TB patients, where treatment entails more drugs 
combined, leading to a substantial risk of suboptimal drug concentrations. Therefore, we 
performed a prospective clinical cohort study in Xiamen, China, regarding drug 
concentrations in relation to individual MICs in MDR-TB patients. We have included 30 
patients and performed a richer sampling protocol for a better estimation of AUC as well as 
MIC and WGS determination (see published study protocol Appendix 1). Similarly to Study 
IV, we used markers of treatment progress such as TTP, TB-score, treatment outcome and a 
quality of life evaluation. The results are currently being analysed and will hopefully shed 
more light regarding drug concentrations in MDR-TB patients. 
Adequate drug exposure is also important in preventing the development of drug resistance 
and low drug concentrations have been associated with acquired drug resistance in clinical 
studies (120, 121, 172). In a multi-centre study in high-endemic countries, up to 46% of 
MDR-TB patients with resistance to a second-line injectable developed XDR-TB during 
treatment (173). Indeed, previous authors have highlighted the importance of 
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pharmacokinetic variability leading to subtherapeutic drug exposure as a cause of resistance, 
through hollow-fibre experiments (174).  
Since low drug concentrations are common and will potentially impair cure and lead to drug 
resistance, increased dose recommendations are being looked into.  
6.2.3.4 Dose recommendations under revision 
There is now supporting evidence that an increased rifampicin dose leads to increased drug 
exposure, without increased toxicity (107). In an important murine experiment from 2003, 
there was a clear relationship between exposure to rifampicin (AUC/MIC) and reduced 
bacterial burden in lung tissue (CFU) (167). Indeed, out of four randomized Phase II trials, all 
apart from one (107) showed that increased rifampicin exposure was associated with a more 
rapid clinical improvement of pulmonary TB (106, 109, 126). There was no effect on the 
final treatment outcome, although the studies were not powered to assess this outcome.   
In a two-week long study, doses up to 35 mg/L were well tolerated and increased bactericidal 
activity was seen in the higher dosing groups (HIGHRIF 1) (113). However, there were only 
15 patients in each dosing group and the study duration was short. In the follow-up study 
HIGHRIF 2 with an extended study period of two months, daily doses of rifampicin 900 and 
1,200 mg resulted in an increased drug exposure but no reduction of time to sputum culture 
conversion, compared to standard treatment (107).  In a three-month long study with 365 
patients (PanACEA MAMS-TB-01), the median time to sputum culture conversion in liquid 
media only (but not on solid) was reduced two weeks for patients treated with 35 mg/kg 
compared to the standard dose of 10 mg/kg of rifampicin, without significant increase in 
toxicity (109).  
Although mainly explored for pulmonary TB, increased dosing to improve treatment 
outcome for TB infections with high mortality, such as TB meningitis, has been studied. 
Despite the promising results of reduced mortality with 13 mg/kg intravenous rifampicin for 
TB meningitis (122), a phase 2 study with 817 patients did not show any benefit of an 
increased oral dose of rifampicin (15 mg/kg) (175), although the dose increase might not have 
been high enough.  
To gain more knowledge from clinical studies regarding increased rifampicin dose, 
pharmacometric modelling studies have been performed. In a modelling study with data from 
the PanACEA MAMS-TB-01 trial, the proportion of patients with sputum culture conversion 
at week 8 increased linearly from 39% with 10 mg/kg to 55% with 35 mg/kg of rifampicin 
(176). Another modelling study based on the same data has shown similar results, where 
higher pyrazinamide exposure was associated with shorter time to sputum culture conversion 
(177). A dose-ranging clinical trial of levofloxacin from 11 mg/kg up to 20 mg/kg for MDR-
TB is ongoing (Opti-Q NCT01918397). 
6.2.3.5 Reducing treatment duration for susceptible TB 
The finding of shortened time to sputum culture conversion by higher rifampicin doses led to 
exploration of a possible reduction in treatment duration for TB, so far only by 
pharmacokinetic modelling studies (176). However, despite convincing pre-clinical data 
(mice data/hollow-fibre) four clinical trials have failed to show support for a shortened four 
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months therapy through the addition of a fluoroquinolone, due to unacceptably high relapse 
rates of 10-20% (71-74). Rifampicin reduces the drug exposure of moxifloxacin around 30% 
(178), which was not taken into consideration as the moxifloxacin dose was not increased. 
Furthermore, it has been suggested that the insufficient sterilising activity of moxifloxacin 
has contributed to increased relapses, since imaging experiments on human lung resections 
have shown low drug concentrations in the caseum of cavities where persisters reside (159). 
This exemplifies that plasma drug concentration is a mere proxy for the drug concentration at 
the site of infection. Colangeli and co-authors recently argued that MIC determinations could 
be an aid in selecting patients with low MICs, where a shorter treatment duration might be 
appropriate (158), although this needs to be evaluated in clinical studies. 
The efforts to reduce treatment duration of TB continue and the ongoing RIFASHORT trial is 
exploring a possible treatment duration of four months with rifampicin 1200 mg or 1800 mg 
(NCT02581527), as well as the NC005 trial with four months of treatment of bedaquiline, 
pretomanid, moxifloxacin and pyrazinamide NCT02193776. Furthermore, the long half-life 
of rifapentine as a way to reduce treatment duration is being studied (NCT02410772).  
6.2.3.6 Reduced treatment duration of MDR-TB 
Owing to its sterilizing effect, pyrazinamide is worth exploring in the quest to shorten MDR-
TB treatment. The addition of pyrazinamide allowed the reduction of treatment of susceptible 
TB from 9 to 6 months (179). Pyrazinamide is currently included in several trials exploring 
new treatment regimens for MDR-TB (STAND, STREAM II, endTB) (86). The optimal dose 
and treatment duration of pyrazinamide should be evaluated, as result of pharmacokinetic 
modelling of clinical data suggest higher doses are needed (180). A synergistic effect of 
pyrazinamide with rifampicin, pretomanid (181) as well as bedaquiline has been seen in 
murine TB (182). Perhaps pyrazinamide might deserve a higher recommendation than 
currently suggested by WHO, where DST is available.  
Clofazimine is another sterilizing drug with activity against hypoxic, non-replicating 
M.tuberculosis in vitro (183). In an RCT with 55 patients in China, the addition of 
clofazimine in the treatment of MDR-TB led to earlier sputum culture conversion and 
increased successful treatment outcome (53.8% compared to 73.6%) (184). 
There are several ongoing clinical studies with new or repurposed drugs exploring the 
optimal regimen and treatment duration of MDR-TB, such as the NExT study (bedaquiline, 
linezolid), STREAM II (bedaquiline), endTB (bedaquiline +/-delamanid) and TB-
PRACTECAL (bedaquiline, pretomanid). The STAND trial is evaluating bedaquiline, 
pretomanid and moxifloxacin for 6 months compared to standard MDR-TB treatment, where 
bedaquiline was added in 2016 to the initial study regimen (NCT03338621), owing to its high 
efficacy and sterilizing properties.  
A more effective, shorter TB-treatment with affordable oral drugs in low-resource settings is 
a key priority. Since there is large variation in disease severity, patient characteristics and 
level of bacterial resistance, perhaps treatment durations need to be individualised more. 
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6.2.4 One size does not fit all – the need to individualise therapy 
Individualised treatment takes multiple factors of a particular individual into account, such as 
clinical, microbiological and pharmacological aspects. Standardised regimens, without taking 
adverse drug reactions and DST results into account, might lead to increased toxicity and 
poorer outcome. Clinical characteristics, such as site of infection and immune status, are 
important to consider, although individual PK characteristics should not be ignored. For 
example, an increased ocular toxicity has been seen in obese patients with weight-based 
dosage of ethambutol. Since ethambutol does not easily distribute in fat-tissue, it should be 
dosed according to lean body weight to avoid overdosing (185).  
Individualised therapy means more than just individualised dosing. If the rifampicin dose is 
doubled due to low drug concentrations, the drug exposure might be more than doubled, due 
to the non-linear kinetics of the drug (107, 126). Therefore, the actual drug concentrations 
need to be measured. 
6.2.4.1 Individualised therapy through therapeutic drug monitoring 
Given the prevalence of subtherapeutic drug concentrations in TB-patients, the possibility of 
TDM in clinical practice is being investigated. Figure 15 visualises a potential scenario of 
how TDM can be implemented clinically. 
Figure 15. Illustration of TDM for tuberculosis treatment in clinical practice.
Illustration Lina Davies Forsman 
Blood for measurements of drug concentrations is collected using limited sampling, when the 
drug is at steady state, typically after two weeks of treatment. Drug concentrations are then 
measured primarily for immunocompromised patients and/or patients at risk of low drug 
concentrations, such as patients with comorbidities (HIV, DM), malabsorption, severe disease 
as well as MDR-TB patients. Drug concentrations are then compared to reference ranges and, 
if available, the individual MIC. Valid PK/PD targets should be developed for the most 
important TB-drugs. 
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Importantly, the MIC value should not be regarded as an outright number, rather a range of 
plausibility of clinical success. An individual MIC should be inflated by at least one two-fold 
dilution or more, depending on the proficiency of the laboratory (186). The site of the disease 
also needs to be taken into account, where extensive cavitary disease or TB meningitis may 
require increased drug exposure. Dose adjustment can then be done if needed and a follow-up 
TDM is performed one or two weeks later. 
As of today, there are no randomized trials evaluating the benefit of TDM for TB and it is not 
likely to be cost-effective for indiscriminate use. Patient groups with the greatest potential 
gain in the use of TDM should be identified; these are most likely to be immunocompromised 
patients with different comorbidities, including diabetes, as well as patients with severe 
infections such as TB-meningitis and disseminated TB. Furthermore, suggested PK/PD 
indices are derived from pre-clinical data and murine models and validation in TB patients is 
needed for valid PK/PD targets. Encouragingly, one of the primary aims of the Opti-Q trial is 
to determine the optimal tolerable AUC/MIC of levofloxacin. TDM at present is a useful 
clinical tool for treatment optimization primarily for immunocompromised and difficult to 
treat TB-patients, patients with slow clinical improvement and patients with MDR-TB, to 
ensure cost-effectiveness. However, the cost of acquired drug resistance or treatment failure 
is very high, both for the patient and society.  
6.2.4.2 Concluding remarks 
In this thesis, individualising TB treatment by taking bacterial resistance, drug exposure and 
disease and patient characteristics into account has been thoroughly discussed. However, any 
clinician knows that there is more to it. We also need to individualise patient care with regard 
to psychological factors such as fear, motivation and need of support. Recently, a Swedish 
mother of three described her MDR-TB treatment as the biggest trauma of her life (187). 
Future research needs to make sure that the treatment is not traumatic.  
In the bigger picture, universal health coverage and addressing social determinants of TB are 
fundamental to curb the TB epidemic (33), especially since the highest burden of TB is in 
low-income countries. Advances in research and new tools must be made universally 
accessible, as well as possible to implement clinically. Multidisciplinary care involving 
clinical pharmacologists and microbiologists, infectious disease physicians, pulmonologists, 
surgeons and counsellors is of great importance. The most significant obstacle against 
individualised therapy is the increased need for surveillance and trained personnel, an extra 
burden on an already stretched health care system. These inequalities must be addressed, for 
no one should have to experience forced isolation away from their family, the stigma of 
having spread TB to your loved ones, the loss of a child to TB or debilitating and sometimes 
permanent side-effects. All TB patients around the world have the same right to optimal care, 
regardless of country of origin and wealth.  
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7 CLINICAL IMPLICATIONS AND CONCLUSIONS 
 
 TMP-SMX and MEM-CLA showed good in vitro activity for MDR/XDR-
M.tuberculosis isolates. Pharmacokinetic modelling indicates that TMP-SMX (i.e. 
Bactrim® forte /co-trimoxazole) can be used at clinically tolerable doses and may be 
considered as an alternative in difficult-to-treat drug-resistant TB.  
 
 MEM-CLA also displayed high in vitro activity against resistant M.tuberculosis 
isolates and meropenem is already recommended by WHO as an add-on drug, in 
combination with the beta-lactamase inhibitor CLA.  
 
 Our results indicate reduced time to sputum culture conversion by the appropriate use 
of PZA. PZA should be added to MDR-TB regimens if DST results indicate 
susceptibility.  
 
 MIC determination might be a useful tool in quantifying resistance and the probability 
of successful treatment outcome of MDR-TB, especially for fluoroquinolones. 
 
 Lower than recommended drug concentrations of first-line TB drugs are common, 
especially with more severe disease.  
 
 The highest proportion of patients with low drug concentrations was seen for 
rifampicin, with significantly higher individual fluctuations compared to other first-
line drugs.  
 
 TDM is an important tool to unveil subtherapeutic drug exposure, especially 
important in severely ill or immunocompromised patients. Both variability in drug 
exposure, as well as the level of MIC, should be considered. 
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8 FUTURE PERSPECTIVES  
 
Speeding up resistance detection – translation of molecular DST 
Molecular techniques can significantly reduce time to DST, if the relationship between 
genotype, phenotype and clinical outcome is clarified. ReSeqTB is a global initiative to 
standardize WGS data analysis and to facilitate the analysis of results. The CRyPTIC 
(Comprehensive Resistance Prediction for Tuberculosis) consortium plans to provide MIC 
determination of 14 common TB-drugs as well as WGS data for more than 30 000 clinical 
M.tuberculosis isolates (188). The aim is to uncover silent and resistance-associated 
mutations and develop an algorithm allowing the identification of resistant as well as 
susceptible isolates (67). Our understanding of the impact on clinical outcome needs to be 
improved. Future developments involve WGS directly from sputa, dealing with 
contamination of human DNA as well as increased accessibility of the technique. Although 
unlikely to replace phenotypic DST globally in the near future, an improved WGS could be 
used to more rapidly guide the initial choice of therapy and for a more individualised 
treatment regimen.  
Dried blood spot in clinical practice  
To further facilitate TDM in clinical practice, dried blood spot (DBS) as a bio-sampling 
method has been developed for many TB-drugs, such as rifampicin (189) and moxifloxacin 
(190). Figure 16 shows DBS sampling with a simple finger-prick, enabling TDM even in 
remote areas, since the DBS card can be stored and transported in room temperature. The 
methodology to analyse DBS should include all main second-line drugs, including 
bedaquiline.  
Figure 16. Finger-prick for dried blood spot sampling.  
 
Photo: Anders Norderman, Medical Image, Karolinska University Hospital Solna  
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Model-based TDM for dosage guidance 
Traditionally, a blood sample is collected after two weeks’ treatment, for the drug to be at 
steady state and to account for autoinduction. With model-based TDM, a few blood samples 
can be collected and analysed already at treatment start, together with information of time of 
drug intake and blood sampling, age, gender and creatinine clearance. The model can then 
predict the optimal dose for that individual, taking autoinduction into account. The dose 
might be further revised when the result of the individual MIC is available, considering MIC 
variability. A model-based TDM approach has been developed for rifampicin by the 
Department of Pharmaceutical Biosciences, Uppsala. Such a tool would enable optimized 
dosages earlier on in treatment. Potential improvement of the model involves the inclusion of 
disease severity, immune status, comorbidities, pharmacogenomics and to develop models for 
groups needing extra attention, such as children and pregnant women. 
There are several promising studies regarding treatment optimization of susceptible and 
MDR-TB (86). There are also a number of TB-specific drugs under investigation 
(www.newtbdrugs.org). Reliable biomarkers are needed to simplify TB trials and improve 
clinical care. This is especially needed regarding treatment length, since patients might 
require different durations of treatment, depending on disease severity and comorbidities.     
A biomarker to guide individualised duration of treatment, as well as a marker predicting risk 
of latent TB infection progressing to active TB, would be ideal.  
Finally, TB deserves attention as the threat to public health and the global emergency it is. 
Regrettably, M.tuberculosis was not even included in the WHO’s list of bacteria in 2017 for 
which new drugs are urgently needed (191). This omission is indefensible; TB should receive 
the utmost attention in governance and policy making and we have to hope that the high-level 
UN-meeting in September 2018 has a substantial impact.   
 
  
  54 
9 ACKNOWLEDGEMENTS   
I am most grateful to everyone who has made this journey such an enjoyable one. Most 
importantly, I would like to thank the study participants for their invaluable contribution. 
These studies were supported by the Swedish National Research Council, Swedish Heart 
Lung Foundation, Research Council of Southeast Sweden and the Swedish Society of 
Medicine. In addition, I would like to give heartfelt thanks to the following: 
Judith, my main supervisor, mentor and friend for her intelligence, unique expertise in the 
field and unwavering support. With a genuine joy for research, a strong sense of justice and 
courage you have been the ideal main supervisor, as well as operating as a much needed 
handbrake at times. 
Thomas, a very dedicated co-supervisor with a critical red-pen that has improved many 
articles, which I’m now grateful of. Widely experienced both in ID and microbiology and 
able to move to a higher gear when needed, you have greatly improved my knowledge with 
your supervision. 
Kristian, for patiently explaining the intricate world of microbiology, even when you took a 
sabbatical to Jamaica. You are an inspiration to me to dare to follow you own path in life. 
Christian, HBTQ-certified microbiologist with profound expertise and reptile-quick answers, 
often marked by a dry sense of humour. Impressive stamina both in working life, as well as 
night life – thanks for guidance. 
My mentor, Anders Eriksson, Professor of Forensic Medicine Umeå, for an excellent 
introduction to research during my years as a medical student. Sven Åke and Kerstin 
Hedström for inspiring me to make the wise choice to change career to Infectious Disease. 
Britta Ryttberg for advising me to do research. Dr Francois Eksteen and Sister Mate and 
all staff at Church of Scotland Hospital, Tugela Ferry, for teaching me about tuberculosis in a 
high-endemic area.  
Xu Biao, Professor of Epidemiology Fudan University, Shangai, for your brilliance and 
tactfulness. Yi Hu, for your hard-work and generosity. Xubin Zheng, dedicated fellow TB-
fighter, for giving me insight in Chinese ways and culture. Xiamen Study team as well as Dr 
Zheng for excellent leadership. Principal Investigator Sven Hoffner, winner ‘Most countries 
travelled to award’ and Professor Vinod Diwan, PHS for your contributions. My exciting 
PhD has meant numerous trips to China and a few months living in Xiamen with my family. 
This was an enjoyable adventure thanks to you all, fēi cháng gǎn xiè! 
My PhD sister Katarina Niward for excellent collaborations with our joint projects with 
meticulous review, support and graphical assistance and Jacob Paues, Linköping. Jan-
Willem Alffenaar, friend and collaborator and soon to be Aussie surfer, for contributing with 
your vast knowledge to the China study. Ulf Hammar, marvellous biostatistician with 
genuine humbleness and for non-pejorative explanation, you are sorely missed. Ulrika 
Simonsson at Uppsala University for enlightening collaborations, with more to come. 
 
Jerker Jonsson for a fruitful collaboration and generosity and Moi for brilliant illustrations 
  55 
and hospitality. All co-workers at the Public Health Agency of Sweden; Jim Werngren, 
Maria Wijkander, Mikael Mansjö, Ramona Groenheit and Michaela Jonsson Nordvall 
for meaningful collaborations and MIC determinations.  
The always so enthusiastic Anna Färnert and the brilliant Kristina Broliden at our 
department for cheering me on. All our hard-working managers at Karolinska University 
Hospital, ably led by Lena Dillner, and with special thanks to Carl ‘Tosse’ Spindler and 
Hedvig Glans for fighting for my research time. Lennart Östlund, the Scheduler with 
capital S, for my schedule for all the years during my research as well as smooth flight 
itineraries all over the world. For superb assistance from our department, with special thanks 
to Anne Rasikari, Lillemor Melander, Eva Johansson and Sara Roth de Alberquerque. 
The Medical Library KS (Marie and Simon), for Endnote support.   
All my wonderful colleagues at the Dep. of Infectious Diseases, not only for support but for 
actually working with patients, allowing me the time to focus on my research. Special thanks 
to fellow research colleagues for valuable tips and invigorating “fikas”; Katja Wyss, John 
Karlsson Valik, Victor Yman, Jan Vesterbacka, and Klara Sondén with special thanks to 
Johanna “STATA-wizard” Kuhlin for selfless sharing of her work. The three musketeers; 
Daniel Holmström (master of toasts), Anna Westman (a.k.a. florist) and Kristina Nilsson – 
I miss my room-mates! Monica Modin, Anna Dahlberg, Lena Jansson, Irene Nordling, 
Debbie Ribjer, study nurses Jan Bellbrant and Ingrid Andrén from the out-patient clinic. 
Charlotta Wagrell for stringent data collection and for the opportunity to practice my 
supervisor skills. Erja Chryssantou for contributing work and TB microbiology expertise. 
Karolinska Institutet for high-quality education especially the Epi Research School with all 
colleagues, in particular Johan Reutfors, Emma Svennberg, Louise Wingård and Robin 
Hofmann. A special thanks to the research-family, Jonas Faxén, Lina Schollin Ask and 
Johanna Rundgren for resolving ‘pek-fekalom’.  
The members of my book club (Robin, Nina, Anna, Erik, Tove, Jakob and Johan) for 
intellectual stimuli on another plane. The Stuga families for much needed relaxation. The 
University gang (Erik, Peter, Mårten, Tobias, Richard and Lars), for the eagerly awaited 
reunions. My oldest friends, the “fika-girls” (especially the Stockholm-branch Lisa, Annelie 
and Joanna) for mandatory three-weekly dinners and wholehearted loyalty. Numerous 
friends such as Paul Garbers and Andreas Nordling for illustrations, Carin Cabrera, 
Anette Hultqvist and kusin-vitamin Klara Arvidsson for lunches and discussions. 
Jenny Stattin for laughter and sustenance. Cina Missailidis, for support and endless 
planning discussions to iron out every last detail and an inspiration to literally and 
figuratively climb mountains; Kaja Heidenreich, for love and always cheering me on. My 
dear Malin Nilsson, for almost daily communication, thanks for always being there for me! 
My mother Christina and my father Mats for always believing in me and giving me the 
courage to explore the world. My sister Vendela ‘the Vet’ for support and insight into a 
workload that makes mine seem insignificant in comparison. Nils and Erik, our adorable and 
laughter-filled children for reminding me what is important in life. Last but not least, my 
beloved husband Brian. Your support, including hours of proof-reading, means so much to 
me. Thanks for making me feel so loved and cherished - with you everything is possible! 
  56 
 
  57 
10 REFERENCES 
1. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. 
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with 
tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575-
80. 
2. Winstrand A, Kulane A, von Schreeb J. [Tuberculosis in Somalia with consequences 
in Sweden]. Lakartidningen. 2010;107(51-52):3279-81. 
3. Public Health Agency of Sweden. Tuberkulos 2017 [Available from: 
http://www.folkhalsomyndigheten.se/amnesomraden/statistik-och-
undersokningar/sjukdomsstatistik/tuberkulos/. 
4. World Health Organization. Global Tuberculosis Report 2018 [Available from: 
http://www.who.int/tb/publications/global_report/en/. 
5. World Health Organization. Global Tuberculosis Report 2015 [Available from: 
http://www.who.int/tb/publications/global_report/en/. 
6. World Health Organization. Global tuberculosis report 2017 [Available from: 
http://apps.who.int/tb/publications/global_report/archive/en/. 
7. van Leth F, van der Werf MJ, Borgdorff MW. Prevalence of tuberculous infection 
and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health 
Organ. 2008;86(1):20-6. 
8. Erkens CG, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, et al. 
Tuberculosis contact investigation in low prevalence countries: a European 
consensus. Eur Respir J. 2010;36(4):925-49. 
9. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care 
in overlapping HIV and TB epidemics. JAMA. 2008;300(4):423-30. 
10. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. 
Tuberculosis control and elimination 2010-50: cure, care, and social development. 
Lancet. 2010;375(9728):1814-29. 
11. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. 
Tuberculosis. Nature Reviews Disease Primers. 2016;2:16076. 
12. Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. 
National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 
2010;88(4):273-80. 
13. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis 
undertaken by the British Medical Research Council tuberculosis units, 1946-1986, 
with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 
2):S231-79. 
14. Millet JP, Shaw E, Orcau A, Casals M, Miro JM, Cayla JA, et al. Tuberculosis 
recurrence after completion treatment in a European city: reinfection or relapse? PLoS 
One. 2013;8(6):e64898. 
15. Murray PR, Baron EJ. Manual of Clinical Microbiology 8th edition ed. Washington 
DC: ASM Press; 2003. 
  58 
16. Iseman MD. A clinician's guide to tuberculosis. Philadelphia USA: Lippincott 
Williams & Wilkins; 2000. 
17. Petersen HJ, Smith AM. The Role of the Innate Immune System in Granulomatous 
Disorders. Front Immunol. 2013;4:120. 
18. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J 
Clin Microbiol Infect Dis. 1994;13(11):908-14. 
19. Hu Y, Liu A, Ortega-Muro F, Alameda-Martin L, Mitchison D, Coates A. High-dose 
rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in 
vitro and in vivo. Front Microbiol. 2015;6:641. 
20. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. 
Tubercle. 1985;66(3):219-25. 
21. Gumbo T, Siyambalapitiyage Dona CSW, Meek C, Leff R. Pharmacokinetics-
Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for 
Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs. 
Antimicrob Agents Chemother. 2009;53(8):3197-204. 
22. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J Suppl. 
2002;36:87s-94s. 
23. Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN, et al. 
The Emergence of Isoniazid-Resistant Cultures in Patients with Pulmonary 
Tuberculosis during Treatment with Isoniazid Alone or Isoniazid Plus Pas. Bull 
World Health Organ. 1964;31(2):273-94. 
24. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of 
antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med. 
2003;167(10):1348-54. 
25. Mitchison DA. Basic mechanisms of chemotherapy. Chest. 1979;76(6 Suppl):771-81. 
26. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial 
cells. Nat Rev Microbiol. 2014;12(3):159-67. 
27. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of 
pathophysiological conditions responsible for altered disposition and pharmacokinetic 
variability. Clin Pharmacokinet. 2005;44(10):1009-34. 
28. Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium 
tuberculosis at different pHs by the radiometric method. Antimicrob Agents 
Chemother. 1988;32(7):1002-4. 
29. Pasipanodya JG, Gumbo T. A new evolutionary and pharmacokinetic-
pharmacodynamic scenario for rapid emergence of resistance to single and multiple 
anti-tuberculosis drugs. Curr Opin Pharmacol. 2011;11(5):457-63. 
30. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: 
update 2015. Int J Tuberc Lung Dis. 2015;19(11):1276-89. 
31. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. 
Int J Tuberc Lung Dis. 2009;13(11):1320-30. 
32. Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. 
Antimicrob Agents Chemother. 2012;56(5):2223-30. 
  59 
33. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's 
new end TB strategy. Lancet. 2015;385(9979):1799-801. 
34. World Health Organization. Global tuberculosis report 2016 [Available from: 
http://apps.who.int/tb/publications/global_report/archive/en/. 
35. Public Health Agency of Sweden. Tuberkulos årsrapport 2017 [Available from: 
https://www.folkhalsomyndigheten.se/folkhalsorapportering-
statistik/statistikdatabaser-och-visualisering/sjukdomsstatistik/tuberkulos/. 
36. Aber VR, Allen BW, Mitchison DA, Ayuma P, Edwards EA, Keyes AB. Quality 
control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive 
cultures and the efficiency of direct smear examination. Tubercle. 1980;61(3):123-33. 
37. Abe C, Hirano K, Wada M, Kazumi Y, Takahashi M, Fukasawa Y, et al. Detection of 
Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and 
Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test. J Clin Microbiol. 
1993;31(12):3270-4. 
38. Babafemi EO, Cherian BP, Banting L, Mills GA, Ngianga K, 2nd. Effectiveness of 
real-time polymerase chain reaction assay for the detection of Mycobacterium 
tuberculosis in pathological samples: a systematic review and meta-analysis. 
Systematic reviews. 2017;6(1):215. 
39. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-
analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, 
for detection of mycobacteria. J Clin Microbiol. 2004;42(5):2321-5. 
40. World Health Organization. Technical report on critical concentrations for drug 
susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis: 
World Health Organization; 2018 [Available from: 
http://apps.who.int/iris/handle/10665/260470. 
41. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. 
embB306 mutations as molecular indicators to predict ethambutol susceptibility in 
Mycobacterium tuberculosis. Chemotherapy. 2012;58(5):358-63. 
42. Kahlmeter G. The 2014 Garrod Lecture: EUCAST - are we heading towards 
international agreement? J Antimicrob Chemother. 2015;70(9):2427-39. 
43. Angeby K, Jureen P, Kahlmeter G, Hoffner SE, Schon T. Challenging a dogma: 
antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull 
World Health Organ. 2012;90(9):693-8. 
44. Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, et al. A 
Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for 
Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis 
Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid. J Clin 
Microbiol. 2016;54(12):2963-8. 
45. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, et al. 
Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance. Bull 
World Health Organ. 1963;29:565-78. 
46. Cohen KA, Bishai WR, Pym AS. Molecular Basis of Drug Resistance in 
Mycobacterium tuberculosis. Microbiol Spectr. 2014;2(3). 
  60 
47. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert(R) 
MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. 
Cochrane Database Syst Rev. 2013(1):CD009593. 
48. Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, et al. Evaluation of 
a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 
2017;377(11):1043-54. 
49. Coovadia YM, Mahomed S, Pillay M, Werner L, Mlisana K. Rifampicin mono-
resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a 
significant phenomenon in a high prevalence TB-HIV region. PLoS One. 
2013;8(11):e77712. 
50. World Health Organization. WHO treatment guidelines for drugresistant tuberculosis 
2016 [Available from: http://apps.who.int/tb/publications/global_report/archive/en/. 
51. Miotto P, Zhang Y, Cirillo DM, Yam WC. Drug resistance mechanisms and drug 
susceptibility testing for tuberculosis. Respirology. 2018. 
52. Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger 
CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-
resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J. 
2017;49(1). 
53. Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KR. GenoType((R)) 
MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane 
Database Syst Rev. 2016;9:Cd010705. 
54. Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks Angela M, Emerson C, et 
al. A standardised method for interpreting the association between mutations and 
phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017;50(6). 
55. Werngren J, Alm E, Mansjo M. Non pncA gene-mutated but pyrazinamide resistant 
M. tuberculosis, why is that? J Clin Microbiol. 2017. 
56. Pankhurst LJ, del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, et al. 
Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome 
sequencing: a prospective study. The Lancet Respiratory Medicine. 2016;4(1):49-58. 
57. Satta G, Lipman M, Smith GP, Arnold C, Kon OM, McHugh TD. Mycobacterium 
tuberculosis and whole-genome sequencing: how close are we to unleashing its full 
potential? Clin Microbiol Infect. 2018;24(6):604-9. 
58. Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, et al. The 
role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: 
report from the EUCAST Subcommittee. Clin Microbiol Infect. 2017;23(1):2-22. 
59. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, et al. Whole-
genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility 
and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15(10):1193-202. 
60. The Cryptic Consortium and the 100 GP. Prediction of Susceptibility to First-Line 
Tuberculosis Drugs by DNA Sequencing. N Engl J Med. 2018;379:1403-15. 
61. Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, et al. Direct whole 
genome sequencing of sputum accurately identifies drug resistant Mycobacterium 
tuberculosis faster than MGIT culture sequencing. J Clin Microbiol. 2018;56(8). 
  61 
62. Rastogi N, Goh KS, David HL. Drug susceptibility testing in tuberculosis: a 
comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 
and 7H11 agar media and a radiometric method. Res Microbiol. 1989;140(6):405-17. 
63. StopTB partnership. Standard Operating Procedure Drug Susceptibility Testing, 
Proportion Method  [Available from: 
http://www.stoptb.org/wg/gli/assets/documents/31_dst_fin.doc. 
64. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility 
testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 
2002;51(1):42-9. 
65. Schon T, Miotto P, Koser CU, Viveiros M, Bottger E, Cambau E. Mycobacterium 
tuberculosis drug-resistance testing: challenges, recent developments and 
perspectives. Clin Microbiol Infect. 2017;23(3):154-60. 
66. Mouton JW, Meletiadis J, Voss A, Turnidge J. Variation of MIC measurements: the 
contribution of strain and laboratory variability to measurement precision. J 
Antimicrob Chemother. 2018;73(9):2374-9. 
67. Rancoita PMV, Cugnata F, Gibertoni Cruz AL, Borroni E, Hoosdally SJ, Walker TM, 
et al. Validating a 14-drug microtitre plate containing bedaquiline and delamanid for 
large-scale research susceptibility testing of Mycobacterium tuberculosis. Antimicrob 
Agents Chemother. 2018;62(9). 
68. Heysell SK, Pholwat S, Mpagama SG, Pazia SJ, Kumburu H, Ndusilo N, et al. 
Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line 
antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs. 
Antimicrob Agents Chemother. 2015;59(11):7104-8. 
69. Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, et 
al. Old drugs, new purpose: retooling existing drugs for optimized treatment of 
resistant tuberculosis. Clin Infect Dis. 2012;55(4):572-81. 
70. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen 
G, et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin 
Infect Dis. 2011;52(9):e194-e9. 
71. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. 
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J 
Med. 2014;371(17):1577-87. 
72. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-
month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 
2014;371(17):1588-98. 
73. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. 
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 
2014;371(17):1599-608. 
74. Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, 
Venkatesan P, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin 
or gatifloxacin containing regimens in the treatment of new sputum positive 
pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030. 
75. Millet J-P, Shaw E, Orcau À, Casals M, Miró JM, Caylà JA, et al. Tuberculosis 
Recurrence after Completion Treatment in a European City: Reinfection or Relapse? 
PLoS One. 2013;8(6):e64898. 
  62 
76. European Centre for Disease Prevention and Control. Tuberculosis surveillance and 
monitoring in Europe 2018 [cited 2018 19th September]. Available from: 
https://ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-
europe-2018. 
77. World Health Organization. Rapid Communication: Key changes to treatment of 
multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) August 2018 
[updated August. Available from: 
http://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf. 
78. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF, Baghaei P, et 
al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant 
tuberculosis: an individual patient data meta-analysis. The Lancet. 
2018;392(10150):821-34. 
79. Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, et al. 
Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-
2004. Int J Tuberc Lung Dis. 2010;14(3):275-81. 
80. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane 
Database Syst Rev. 2007(4):CD003343. 
81. Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, et al. Linezolid Trough 
Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the 
Treatment of Chronic Extensively Drug-Resistant Tuberculosis. EBioMedicine. 
2015;2(11):1627-33. 
82. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. 
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among 
over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180-7. 
83. Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, Trebucq A. High 
effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc 
Lung Dis. 2015;19(5):517-24. 
84. Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, et al. 
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in 
Europe. Am J Respir Crit Care Med. 2016;194(8):1029-31. 
85. The Union. STREAM clinical trial results provide vital insight into nine-month 
treatment regimen for multidrug-resistant tuberculosis web page2017 [Available 
from: https://www.theunion.org/news-centre/news/stream-clinical-trial-results-
provide-vital-insight-into-nine-month-treatment-regimen-for-multidrug-resistant-
tuberculosis. 
86. Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant 
tuberculosis: An update on disease burden, diagnosis and treatment. Respirology. 
2018;23(7):656-73. 
87. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, et al. 
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N 
Engl J Med. 2015;373(20):1986-8. 
88. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, Roberts GD. 
Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 
2009;53(11):4789-93. 
  63 
89. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, 3rd, Blanchard JS. Meropenem-
clavulanate is effective against extensively drug-resistant Mycobacterium 
tuberculosis. Science. 2009;323(5918):1215-8. 
90. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for 
treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 
2005;49(7):2816-21. 
91. Wallis RS, Nacy C. Early bactericidal activity of new drug regimens for tuberculosis. 
The Lancet. 2013;381(9861):111-2. 
92. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. 
Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J 
Med. 2014;371(8):723-32. 
93. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, et al. Biomarkers 
and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet. 
2010;375(9729):1920-37. 
94. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. 
Sputum culture conversion as a prognostic marker for end-of-treatment outcome in 
patients with multidrug-resistant tuberculosis: a secondary analysis of data from two 
observational cohort studies. The Lancet Respiratory medicine. 2015;3(3):201-9. 
95. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum 
monitoring during tuberculosis treatment for predicting outcome: systematic review 
and meta-analysis. Lancet Infect Dis. 2010;10(6):387-94. 
96. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. 
Evaluation of sputum culture conversion as a prognostic marker for end-of-treatment 
outcome inpatients with multidrug-resistant tuberculosis. The Lancet Respiratory 
medicine. 2015;3(3):201-9. 
97. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald 
PR, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and 
moxifloxacin combinations: a randomised trial. Lancet. 2012;380(9846):986-93. 
98. Diacon AH, Dawson R, Groote-Bidlingmaier Fv, Symons G, Venter A, Donald PR, et 
al. Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in 
Combinations with Pretomanid and Bedaquiline. Am J Respir Crit Care Med. 
2015;191(8):943-53. 
99. Somoskovi A, Magyar P. Comparison of the mycobacteria growth indicator tube with 
MB redox, Lowenstein-Jensen, and Middlebrook 7H11 media for recovery of 
mycobacteria in clinical specimens. J Clin Microbiol. 1999;37(5):1366-9. 
100. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. Time to 
liquid culture positivity can substitute for colony counting on agar plates in early 
bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect. 
2012;18(7):711-7. 
101. Epstein MD, Schluger NW, Davidow AL, Bonk S, Rom WN, Hanna B. Time to 
detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in 
patients receiving treatment for pulmonary tuberculosis. Chest. 1998;113(2):379-86. 
102. Rudolf F. The Bandim TBscore--reliability, further development, and evaluation of 
potential uses. Glob Health Action. 2014;7:24303. 
  64 
103. Tozer TN, Rowland M. Introduction to pharmacokinetics and pharmacodynamics : 
the quantitative basis of drug therapy. Philadelphia: Lippincott Williams & Wilkins; 
2006. 
104. Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, et al. 
Current status and opportunities for therapeutic drug monitoring in the treatment of 
tuberculosis. Expert Opin Drug Metab Toxicol. 2016;12(5):509-21. 
105. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of 
pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an 
update. J Antimicrob Chemother. 2005;55(5):601-7. 
106. Velasquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vasquez D, Sanchez 
Garavito E, et al. ERS Special Article. Efficacy and Safety of High-Dose Rifampin in 
Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care 
Med. 2018;198(5):657-66. 
107. Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, et al. 
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin 
Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary 
Tuberculosis. Antimicrob Agents Chemother. 2017;61(11). 
108. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for 
diabetes related tuberculosis associate with hastened sputum microbiological 
clearance in Virginia, USA. BMC Infect Dis. 2017;17:125. 
109. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-
dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, 
multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39-49. 
110. Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, et al. 
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary 
Tuberculosis. Clin Infect Dis. 2017;64(10):1350-9. 
111. Heemskerk AD, Bang ND, Mai NT, Chau TT, Phu NH, Loc PP, et al. Intensified 
Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med. 
2016;374(2):124-34. 
112. Maze MJ, Paynter J, Chiu W, Hu R, Nisbet M, Lewis C. Therapeutic drug monitoring 
of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New 
Zealand. Int J Tuberc Lung Dis. 2016;20(7):955-60. 
113. Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-
ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J 
Respir Crit Care Med. 2015;191(9):1058-65. 
114. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, et al. 
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary 
kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents 
Chemother. 2015;59(1):38-45. 
115. Mah A, Kharrat H, Ahmed R, Gao Z, Der E, Hansen E, et al. Serum drug 
concentrations of INH and RMP predict 2-month sputum culture results in 
tuberculosis patients. Int J Tuberc Lung Dis. 2015;19(2):210-5. 
116. Meloni M, Corti N, Muller D, Henning L, Gutteck U, von Braun A, et al. Cure of 
tuberculosis despite serum concentrations of antituberculosis drugs below published 
reference ranges. Swiss Med Wkly. 2015;145:w14223. 
  65 
117. Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, et al. Serum Levels of 
Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. 
Antimicrob Agents Chemother. 2016;60(1):92-8. 
118. Prahl JB, Johansen IS, Cohen AS, Frimodt-Moller N, Andersen AB. Clinical 
significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a 
prospective observational study. J Antimicrob Chemother. 2014;69(10):2841-7. 
119. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, et al. 
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment 
response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents 
Chemother. 2013;57(8):3614-9. 
120. Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC. Therapeutic drug 
monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc 
Lung Dis. 2013;17(2):221-4. 
121. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug 
concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 
2013;208(9):1464-73. 
122. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. 
Intensified regimen containing rifampicin and moxifloxacin for tuberculous 
meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 
2013;13(1):27-35. 
123. Requena-Méndez A, Davies G, Ardrey A, Jave O, López-Romero SL, Ward SA, et al. 
Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without 
Comorbid Diabetes or HIV. Antimicrob Agents Chemother. 2012;56(5):2357-63. 
124. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. 
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment 
outcomes among a predominantly HIV-infected cohort of adults with tuberculosis 
from Botswana. Clin Infect Dis. 2009;48(12):1685-94. 
125. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, et al. Peak plasma 
rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin 
Microbiol Infect Dis. 2008;27(6):467-72. 
126. Ruslami R, Nijland HMJ, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. 
Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard 
Dose in Pulmonary Tuberculosis Patients. Antimicrob Agents Chemother. 
2007;51(7):2546-51. 
127. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, van der Meer 
JW, et al. Low plasma concentrations of rifampicin in tuberculosis patients in 
Indonesia. Int J Tuberc Lung Dis. 2002;6(6):497-502. 
128. Narita M, Hisada M, Thimmappa B, Stambaugh J, Ibrahim E, Hollender E, et al. 
Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, 
human immunodeficiency virus status, and other risk factors. Clin Infect Dis. 
2001;32(3):515-7. 
129. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. 
Eur Respir J. 2005;25(3):564-9. 
  66 
130. Salman H Siddiqi SR-G. MGIT Procedure Manual: FIND Diagnostics; 2006 
[Available from: https://www.finddx.org/wp-
content/uploads/2016/02/mgit_manual_nov2006.pdf. 
131. Siddiqi SH. MGIT Procedure Manual: FIND Diagnostics; 2006 [Available from: 
https://www.finddx.org/wp-content/uploads/2016/02/mgit_manual_nov2006.pdf. 
132. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The 
epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-
resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet 
Respiratory medicine. 2017. 
133. Ekblom R, Wolf JBW. A field guide to whole-genome sequencing, assembly and 
annotation. Evolutionary Applications. 2014;7(9):1026-42. 
134. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH, van Helden P, et al. Whole-
genome sequencing to establish relapse or re-infection with Mycobacterium 
tuberculosis: a retrospective observational study. The Lancet Respiratory medicine. 
2013;1(10):786-92. 
135. Pitt JJ. Principles and Applications of Liquid Chromatography-Mass Spectrometry in 
Clinical Biochemistry. The Clinical Biochemist Reviews. 2009;30(1):19-34. 
136. Rothman K. Epidemiology- An introduction. 2nd ed. New York, USA: Oxford 
University Press; 2012. 
137. Carneiro I, Howard N. Introduction to Epidemiology. 2nd ed: London School of 
Hygiene and Tropical Medicine; 2011. 
138. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis Part III: 
multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J 
Cancer. 2003;89(4):605-11. 
139. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. New York: Oxford 
University Press; 2013. 
140. Cheng AC, McBryde ES, Wuthiekanun V, Chierakul W, Amornchai P, Day NP, et al. 
Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis. 
Antimicrob Agents Chemother. 2009;53(10):4193-9. 
141. Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf 
TS, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant 
tuberculosis. Eur Respir J. 2013;42(2):504-12. 
142. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and validation. J Chronic 
Dis. 1987;40(5):373-83. 
143. Alsaad N, van der Laan T, van Altena R, Wilting KR, van der Werf TS, Stienstra Y, 
et al. Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis. 
Int J Antimicrob Agents. 2013;42(5):472-4. 
144. Cavanaugh JS, Jou R, Wu MH, Dalton T, Kurbatova E, Ershova J, et al. 
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional 
drugs compared with their reported pharmacokinetic/pharmacodynamic parameters. J 
Antimicrob Chemother. 2017;72(6):1678-87. 
  67 
145. Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf 
TS, et al. Evaluation of co-trimoxazole in treatment of multidrug-resistant 
tuberculosis. Eur Respir J. 2013;42(2):504-12. 
146. Davies Forsman L, Schon T, Simonsson US, Bruchfeld J, Larsson M, Jureen P, et al. 
Intra- and Extracellular Activities of Trimethoprim-Sulfamethoxazole against 
Susceptible and Multidrug-Resistant Mycobacterium tuberculosis. Antimicrob Agents 
Chemother. 2014;58(12):7557-9. 
147. Gonzalo X, Drobniewski F. Is there a place for beta-lactams in the treatment of 
multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between 
meropenem and amoxicillin/clavulanate. J Antimicrob Chemother. 2013;68(2):366-9. 
148. Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, 
Garcia-Basteiro AL, et al. beta-Lactams against Tuberculosis--New Trick for an Old 
Dog? N Engl J Med. 2016;375(4):393-4. 
149. Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, et al. 
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical 
experience. Eur Respir J. 2016;47(1):333-6. 
150. Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, et 
al. Comparison of effectiveness and safety of imipenem/clavulanate- versus 
meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. 
Eur Respir J. 2016;47(6):1758-66. 
151. Zhang D, Wang Y, Lu J, Pang Y. In Vitro Activity of beta-Lactams in Combination 
with beta-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium 
tuberculosis Isolates. Antimicrob Agents Chemother. 2016;60(1):393-9. 
152. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the 
efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem 
in the treatment of complicated intra-abdominal infections in hospitalized adults: 
results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 
2013;68(5):1183-92. 
153. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs 
piperacillin-tazobactam on clinical cure or improvement and microbial eradication in 
complicated urinary tract infection: The tango i randomized clinical trial. JAMA. 
2018;319(8):788-99. 
154. Hazra S, Xu H, Blanchard JS. Tebipenem, a new carbapenem antibiotic, is a slow 
substrate that inhibits the beta-lactamase from Mycobacterium tuberculosis. 
Biochemistry. 2014;53(22):3671-8. 
155. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: 
international clinical experience based on the first 3125 patients treated with 
meropenem. J Antimicrob Chemother. 1995;36 Suppl A:207-23. 
156. Zuercher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, et al. Drug 
susceptibility testing and mortality in patients treated for tuberculosis in high-burden 
countries. bioRxiv. 2018. 
157. Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. Redefining multidrug-
resistant tuberculosis based on clinical response to combination therapy. Antimicrob 
Agents Chemother. 2014;58(10):6111-5. 
  68 
158. Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, et al. 
Bacterial Factors That Predict Relapse after Tuberculosis Therapy. N Engl J Med. 
2018;379(9):823-33. 
159. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O’Brien P, et al. The 
association between sterilizing activity and drug distribution into tuberculosis lesions. 
Nat Med. 2015;21(10):1223-7. 
160. Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar 
JC. Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose 
Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis 
Programmes. Clin Infect Dis. 2018. 
161. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based 
on antimicrobial pharmacokinetic/pharmacodynamic science and population 
pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54(4):1484-91. 
162. European Committee on Antimicrobial Susceptibility testing (EUCAST). Modifying 
the definitions of S, I and R and introducing the Area of Technical Uncertainty. 
[Available from: 
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/2018/
EUCAST_intermediate_2018_February_23_General_Consultation.pdf. 
163. Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J. Therapeutic drug 
monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J 
Tuberc Lung Dis. 2016;20(6):819-26. 
164. Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran 
G, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a 
systematic review and meta-analysis. J Antimicrob Chemother. 2018. 
165. Koegelenberg CF, Nortje A, Lalla U, Enslin A, Irusen EM, Rosenkranz B, et al. The 
pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care. 
S Afr Med J. 2013;103(6):394-8. 
166. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 
Pharmacokinetics of oral and intravenous rifampicin during chronic administration. 
Klin Wochenschr. 1985;63(23):1205-11. 
167. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, et al. 
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of 
tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118-24. 
168. Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE, Jr., Jelliffe RW. 
Population modeling and Monte Carlo simulation study of the pharmacokinetics and 
antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents 
Chemother. 2009;53(7):2974-81. 
169. Prahl J. Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in 
patients with tuberculosis: Aarhus University; 2014. 
170. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. Rifampicin 
concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and 
serum following a single 600 mg oral dose in patients undergoing fibre-optic 
bronchoscopy. J Antimicrob Chemother. 2002;50(6):1011-5. 
171. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 
genotype guided regimen reduces isoniazid-induced liver injury and early treatment 
  69 
failure in the 6-month four-drug standard treatment of tuberculosis: a randomized 
controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 
2013;69(5):1091-101. 
172. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, et al. 
Association between acquired rifamycin resistance and the pharmacokinetics of 
rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 
2005;40(10):1481-91. 
173. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, et 
al. Extensive drug resistance acquired during treatment of multidrug-resistant 
tuberculosis. Clin Infect Dis. 2014;59(8):1049-63. 
174. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant 
tuberculosis not due to noncompliance but to between-patient pharmacokinetic 
variability. J Infect Dis. 2011;204(12):1951-9. 
175. Heemskerk AD, Bang ND, Mai NTH, Chau TTH, Phu NH, Loc PP, et al. Intensified 
Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med. 
2016;374(2):124-34. 
176. Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, et 
al. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating 
Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin 
Infect Dis. 2018;67(1):34-41. 
177. Savic R, Peloquin C, Boeree M. The relationship between pyrazinamide 
pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB 
receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 
28 and PanACEA MAMS. Presented at: Ninth International Workshop on Clinical 
Pharmacology of TB Drugs; 2016; Liverpool, United Kingdom. 
178. Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, et al. 
Rifampicin reduces plasma concentrations of moxifloxacin in patients with 
tuberculosis. Clin Infect Dis. 2007;45(8):1001-7. 
179. Combs DL, O'Brien RJ, Geiter LJ. Usphs tuberculosis short-course chemotherapy 
trial 21: Effectiveness, toxicity, and acceptability: the report of final results. Ann 
Intern Med. 1990;112(6):397-406. 
180. Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, et al. 
Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. 
Antimicrob Agents Chemother. 2017;61(6). 
181. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced Bactericidal 
Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine 
Model of Tuberculosis. Antimicrob Agents Chemother. 2008;52(10):3664-8. 
182. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, et al. 
Synergistic Activity of R207910 Combined with Pyrazinamide against Murine 
Tuberculosis. Antimicrob Agents Chemother. 2007;51(3):1011-5. 
183. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. Low-oxygen-
recovery assay for high-throughput screening of compounds against nonreplicating 
Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007;51(4):1380-5. 
  70 
184. Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, et al. Clofazimine for the treatment of 
multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled 
study in China. Clin Infect Dis. 2015;60(9):1361-7. 
185. Hasenbosch RE, Alffenaar JW, Koopmans SA, Kosterink JG, van der Werf TS, van 
Altena R. Ethambutol-induced optical neuropathy: risk of overdosing in obese 
subjects. Int J Tuberc Lung Dis. 2008;12(8):967-71. 
186. Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based 
dose adjustment: facts and fables. J Antimicrob Chemother. 2018;73(9):2585-6. 
187. Medicinsk Vetenskap. Lång väg tillbaka efter TBC-diagnosen 2018 [Available from: 
https://ki.se/forskning/lang-vag-tillbaka-efter-tbc-diagnosen. 
188. CRyPTIC. Comprehensive Resistance Prediction for Tuberculosis: an International 
Consortium  [updated December 22 2017. Available from: 
http://www.crypticproject.org/. 
189. Allanson AL, Cotton MM, Tettey JN, Boyter AC. Determination of rifampicin in 
human plasma and blood spots by high performance liquid chromatography with UV 
detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal. 
2007;44(4):963-9. 
190. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of 
moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit 
and blood volume. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(15-
16):1063-70. 
191. Burki TK. Tuberculosis missing from WHO bacteria list. The Lancet Respiratory 
medicine. 2017;5(4):252. 
 
